0001224608falsetrue00012246082024-07-292024-07-290001224608us-gaap:CommonStockMember2024-07-292024-07-290001224608cno:RightsToPurchaseSeriesFJuniorParticipatingPreferredStockMember2024-07-292024-07-290001224608cno:A5125SubordinatedDebenturesDue2060Member2024-07-292024-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 29, 2024
CNO Financial Group, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | | | | | |
Delaware | 001-31792 | 75-3108137 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
11299 Illinois Street
Carmel, Indiana 46032
(Address of Principal Executive Offices) (Zip Code)
(317) 817-6100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol | | Name of each exchange on which registered |
Common Stock, par value $0.01 per share | | CNO | | New York Stock Exchange |
Rights to purchase Series F Junior Participating Preferred Stock | | | | New York Stock Exchange |
5.125% Subordinated Debentures due 2060 | | CNOpA | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
Item 2.02. | Results of Operations and Financial Condition. |
On July 29, 2024, CNO Financial Group, Inc. ("CNO" or the "Company") issued: (i) a press release announcing its financial results for the quarter ended June 30, 2024, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference; (ii) the Quarterly Financial Supplement for June 30, 2024, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference; and (iii) additional financial information related to its financial and operating results for the quarter ended June 30, 2024, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.
The information contained under Item 2.02 in this Current Report on Form 8-K (including Exhibits 99.1, 99.2 and 99.3) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information contained in this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| | | | | |
Item 9.01(d). | Financial Statements and Exhibits. |
The following materials are furnished as exhibits to this Current Report on Form 8-K:
| | | | | |
99.1 | |
99.2 | |
99.3 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
| CNO Financial Group, Inc. |
| |
Date: July 29, 2024 | |
| By: | /s/ Michellen A. Wildin | |
| | Michellen A. Wildin | |
| | Senior Vice President and Chief Accounting Officer | |
| | |
Exhibit 99.1
News
For Immediate Release
CNO Financial Group Reports Second Quarter 2024 Results
Earnings per share up 66%; Operating earnings per share up 94%
Carmel, Ind., July 29, 2024 - CNO Financial Group, Inc. (NYSE: CNO) today reported net income of $116.3 million, or $1.06 per diluted share, in 2Q24 compared to $73.7 million, or $0.64 per diluted share, in 2Q23. Net operating income (1) was $114.6 million, or $1.05 per diluted share, in 2Q24 compared to $62.3 million, or $0.54 per diluted share, in 2Q23.
"CNO delivered excellent earnings and operating performance across the board, led by continued sales momentum, a growing agent force, and strong underwriting margins and net investment income in the quarter," said Gary C. Bhojwani, chief executive officer. "Sales grew for the eighth consecutive quarter, illustrating the strength of our broad product offerings and diverse distribution model to serve the middle-income market."
"All of our Growth Scorecard performance metrics were up in the quarter. Our capital position remained strong as we increased book value per share, while returning more than $77 million to shareholders."
"CNO enters the second half of the year with consistent sales momentum and continuing favorable macro trends. We remain well-positioned to deliver sustainable profitable growth and long-term shareholder value."
Second Quarter 2024 Highlights (as compared to the corresponding period in the prior year where applicable)
• Total new annualized premiums ("NAP") (4) up 4%; Worksite Division NAP up 18%; Consumer Division NAP up 2%
•Medicare Supplement NAP up 16%; Medicare Advantage policies sold up 78%
•Annuity collected premiums up 9%; Policyholder and client assets up 9%
• Returned $77.2 million to shareholders
• Book value per share was $22.80, up 30%; book value per diluted share, excluding accumulated other comprehensive loss, (2) was $36.00, up 11%
• Return on equity ("ROE") of 19.9%; operating ROE, as adjusted, (5) of 11.2%
•Raising full-year guidance on earnings and cash flow
FINANCIAL SUMMARY
Quarter End
(Amounts in millions, except per share data)
(Unaudited)
Net operating income, a non-GAAP(a) financial measure, is used consistently by CNO’s management to evaluate the operating performance of the Company and is a measure commonly used in the life insurance industry. It differs from net income primarily because it excludes certain non-operating items such as net realized investment gains (losses) from sales and change in the allowance for credit losses, changes in fair values of embedded derivatives and market risk benefits and the liability for a deferred compensation plan, and certain significant and unusual items included in net income. Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company’s business. Net income is the most directly comparable GAAP measure.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Per diluted share | | | | | | | |
| Quarter ended | | Quarter ended |
| June 30, | | June 30, |
| 2024 | | | 2023 | | % change | | 2024 | | | 2023 | | % change |
| | | | | | | | | | | | | |
Income from insurance products (b) | $ | 1.10 | | | | $ | 0.64 | | | 72 | | | $ | 120.5 | | | | $ | 73.7 | | | 64 | |
Fee income | 0.01 | | | | — | | | n/m | | 0.8 | | | | 0.6 | | | 33 | |
Investment income not allocated to product lines (c) | 0.41 | | | | 0.24 | | | 71 | | | 44.8 | | | | 28.0 | | | 60 | |
Expenses not allocated to product lines | (0.16) | | | | (0.18) | | | (11) | | | (17.5) | | | | (21.1) | | | (17) | |
Operating earnings before taxes | 1.36 | | | | 0.70 | | | | | 148.6 | | | | 81.2 | | | |
Income tax expense on operating income | (0.31) | | | | (0.16) | | | 94 | | | (34.0) | | | | (18.9) | | | 80 | |
Net operating income (1) | 1.05 | | | | 0.54 | | | 94 | | | 114.6 | | | | 62.3 | | | 84 | |
Net realized investment losses from sales and change in allowance for credit losses | (0.20) | | | | (0.27) | | | | | (21.9) | | | | (31.3) | | | |
Net change in market value of investments recognized in earnings | 0.04 | | | | (0.04) | | | | | 4.7 | | | | (4.0) | | | |
Changes in fair value of embedded derivative liabilities and market risk benefits | 0.15 | | | | 0.44 | | | | | 16.8 | | | | 50.4 | | | |
| | | | | | | | | | | | | |
Other | 0.02 | | | | — | | | | | 2.4 | | | | (0.2) | | | |
Non-operating income before taxes | 0.01 | | | | 0.13 | | | | | 2.0 | | | | 14.9 | | | |
Income tax expense on non-operating income | — | | | | (0.03) | | | | | (0.3) | | | | (3.5) | | | |
| | | | | | | | | | | | | |
Net non-operating income | 0.01 | | | | 0.10 | | | | | 1.7 | | | | 11.4 | | | |
Net income | $ | 1.06 | | | | $ | 0.64 | | | | | $ | 116.3 | | | | $ | 73.7 | | | |
| | | | | | | | | | | | | |
Weighted average diluted shares outstanding | 109.3 | | | | 115.6 | | | | | | | | | | |
n/m - not meaningful
____________________
(a) GAAP is defined as accounting principles generally accepted in the United States of America.
(b) Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Insurance margin is management’s measure of the profitability of its annuity, health and life segments’ performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs.
(c) Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed notes ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders.
FINANCIAL SUMMARY (continued)
Management vs. GAAP Measures
(Dollars in millions, except per share data)
(Unaudited)
Shareholders’ equity, excluding accumulated other comprehensive income (loss), and book value per share, excluding accumulated other comprehensive income (loss), are non-GAAP measures that are utilized by management to view the business without the effect of accumulated other comprehensive income (loss) which is primarily attributable to fluctuations in interest rates associated with fixed maturities, available for sale. Management views the business in this manner because the Company has the ability and generally, the intent, to hold investments to maturity and meaningful trends can be more easily identified without the fluctuations. In addition, shareholders' equity excludes net operating loss carryforwards in our non-GAAP return on equity measures as such assets are not discounted and, accordingly, will not provide a return to shareholders until after it is realized as a reduction to taxes that would otherwise be paid. Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns.
___________________________________________________________________________________________________
| | | | | | | | | | | |
| Quarter ended |
| June 30, |
| 2024 | | 2023 |
| | | |
Trailing twelve months return on equity (a) | 19.9 | % | | 14.8 | % |
Trailing twelve months operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) (5) | 11.2 | % | | 8.0 | % |
Trailing twelve months operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) (5) | 10.0 | % | | 8.0 | % |
| | | |
| | | |
Shareholders’ equity | $ | 2,428.9 | | | $ | 1,995.8 | |
Accumulated other comprehensive loss | 1,464.3 | | | 1,733.5 | |
| | | |
Shareholders’ equity, excluding accumulated other comprehensive loss | 3,893.2 | | | 3,729.3 | |
Net operating loss carryforwards | (296.5) | | | (126.3) | |
Shareholders' equity, excluding accumulated other comprehensive loss and net operating loss carryforwards | $ | 3,596.7 | | | $ | 3,603.0 | |
| | | |
Book value per diluted share | $ | 22.46 | | | $ | 17.31 | |
Accumulated other comprehensive loss | 13.54 | | | 15.03 | |
| | | |
Book value per diluted share, excluding accumulated other comprehensive loss (a non-GAAP financial measure) (2) | $ | 36.00 | | | $ | 32.34 | |
____________________
(a) Calculated using average shareholders’ equity for the measurement period.
Non-Operating Items
Net investment losses in 2Q24 were $21.9 million net of a reduction in the allowance for credit losses of $4.1 million. Net investment losses in 2Q23 were $31.3 million including an increase in the allowance for credit losses of $9.9 million.
During 2Q24 and 2Q23, we recognized an increase (decrease) in earnings of $4.7 million and $(4.0) million, respectively, due to the net change in market value of investments.
During 2Q24 and 2Q23, we recognized an increase in earnings of $16.8 million and $50.4 million, respectively, resulting from changes in the estimated fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities. Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and market risk benefits.
In 2Q24, other non-operating items included an increase in earnings of $3.5 million for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability. We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change.
INVESTMENT PORTFOLIO
(Dollars in millions)
Fixed maturities, available for sale, at amortized cost by asset class as of June 30, 2024 are as follows:
| | | | | | | | | | | | | | | | | |
| Investment grade | | Below investment grade | | Total |
Corporate securities | $ | 12,849.3 | | | $ | 601.4 | | | $ | 13,450.7 | |
Certificates of deposit | 470.2 | | | — | | | 470.2 | |
United States Treasury securities and obligations of the United States government and agencies | 278.6 | | | — | | | 278.6 | |
States and political subdivisions | 3,182.9 | | | 9.6 | | | 3,192.5 | |
Foreign governments | 101.1 | | | — | | | 101.1 | |
Asset-backed securities | 1,448.4 | | | 103.8 | | | 1,552.2 | |
Agency residential mortgage-backed securities | 787.3 | | | — | | | 787.3 | |
Non-agency residential mortgage-backed securities | 1,231.7 | | | 435.5 | | (a) | 1,667.2 | |
Collateralized loan obligations | 1,227.6 | | | — | | | 1,227.6 | |
Commercial mortgage-backed securities | 2,290.1 | | | 88.6 | | | 2,378.7 | |
| | | | | |
Total | $ | 23,867.2 | | | $ | 1,238.9 | | | $ | 25,106.1 | |
____________________
(a) Certain structured securities rated below investment grade by Nationally Recognized Statistical Rating Organizations may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the National Association of Insurance Commissioners (NAIC).
The fair value of CNO’s available for sale fixed maturity portfolio was $22.6 billion compared with an amortized cost of $25.1 billion. Net unrealized losses were comprised of gross unrealized gains of $113.2 million and gross unrealized losses of $2,561.6 million. The allowance for credit losses was $39.8 million at June 30, 2024.
Statutory (based on non-GAAP measures) and GAAP Capital Information
The consolidated statutory risk-based capital ratio of our U.S. based insurance subsidiaries was estimated at 394% at June 30, 2024, reflecting estimated 2Q24 statutory operating earnings of $28 million (and $24 million in the first six months of 2024) and the payment of insurance company dividends (net of capital contributions) to the holding company of $29.7 million during 2Q24 (and $73.0 million (net of capital contributions) in the first six months of 2024).
During 2Q24, we repurchased $60.0 million of common stock under our securities repurchase program (including $1.1 million of repurchases settled in 3Q24). We repurchased 2.2 million common shares at an average cost of $27.61 per share. As of June 30, 2024, we had 106.5 million shares outstanding and had authority to repurchase up to an additional $421.8 million of our common stock. During 2Q24, dividends paid on common stock totaled $17.2 million.
Unrestricted cash and investments held by our holding company were $429 million at June 30, 2024, compared to $256 million at December 31, 2023. In addition, the holding company has invested $500 million of the proceeds from the previously announced issuance of $700.0 million of 6.450% senior notes due 2034 (the "2034 Notes") primarily into certificates of deposit which are expected to be used for the repayment of $500.0 million of 5.250% senior notes due May 2025 (the "2025 Notes").
Book value per common share was $22.80 at June 30, 2024 compared to $20.26 at December 31, 2023. Book value per diluted share, excluding accumulated other comprehensive income (loss) (2), was $36.00 at June 30, 2024, compared to $33.94 at December 31, 2023.
The debt-to-capital ratio was 43.0% and 34.0% at June 30, 2024 and December 31, 2023, respectively. Our debt-to-total capital ratio, excluding accumulated other comprehensive income (loss) (3) was 32.0% and 23.1% at June 30, 2024 and December 31, 2023, respectively. Such debt-to-total capital ratios reflect the issuance of the 2034 Notes in May 2024. At June 30, 2024, adjusting for the expected repayment of the 2025 Notes, the debt-to-total capital ratio would have been 35.4% and the debt-to-total capital ratio, excluding accumulated other comprehensive income (loss), would have been 25.5%.
Return on equity for the trailing four quarters ended June 30, 2024 and 2023, was 19.9% and 14.8%, respectively. Operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (5) for the trailing four quarters ended June 30, 2024 and 2023, was 10.0% and 8.0%, respectively.
In this news release, CNO includes non-GAAP measures to enhance investors’ understanding of management’s view of the business. The non-GAAP measures are not a substitute for GAAP, but rather a supplement to increase transparency by providing a broader perspective. CNO’s definitions of non-GAAP measures may differ from other companies’ definitions. More detailed information including various GAAP and non-GAAP measurements are located at CNOinc.com in the Investors section under SEC Filings.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS:
This press release may contain forward-looking statements within the meaning of federal securities laws. These prospective statements reflect management’s current expectations, but are not guarantees of future performance. Accordingly, please refer to CNO’s cautionary statement regarding forward-looking statements, and the business environment in which the Company operates, contained in the Company’s Form 10-K for the year ended December 31, 2023 and any subsequent Form 10-Q or Form 10-K on file with the Securities and Exchange Commission and on the Company’s website at CNOinc.com in the Investors section. CNO specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.
EARNINGS RELEASE CONFERENCE CALL WEBCAST:
The Company will host a conference call to discuss results on July 30, 2024 at 11:00 a.m. Eastern Time. During the call, we will be referring to a presentation that will be available at the Investors section of the company's website.
To participate by dial-in, please register at https://www.netroadshow.com/events/login?show=51d949bc&confId=68394. Upon registering, you will be provided with call details and a registrant ID used to track attendance on the conference call. Reminders will also be sent to registered participants via email.
For those investors who prefer to listen to the call online, we will be broadcasting the call live via webcast. The event can be accessed through the Investors section of the company's website: ir.CNOinc.com. Participants should go to the website at least 15 minutes before the event to register and download any necessary audio software.
ABOUT CNO FINANCIAL GROUP
CNO Financial Group, Inc. (NYSE: CNO) secures the future of middle-income America. CNO provides life and health insurance, annuities, financial services, and workforce benefits solutions through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income, and retirement needs with 3.2 million policies and $36 billion in total assets. Our 3,500 associates, 4,800 exclusive agents and more than 5,000 independent partner agents guide individuals, families, and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.
CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
(Dollars in millions)
(unaudited)
| | | | | | | | | | | |
| June 30, 2024 | | December 31, 2023 |
ASSETS | | | |
Investments: | | | |
Fixed maturities, available for sale, at fair value (net of allowance for credit losses: June 30, 2024 - $39.8 and December 31, 2023 - $42.9; amortized cost: June 30, 2024 - $25,106.1 and December 31, 2023 - $23,699.2) | $ | 22,617.9 | | | $ | 21,506.2 | |
Equity securities at fair value | 117.7 | | | 96.9 | |
Mortgage loans (net of allowance for credit losses: June 30, 2024 - $13.2 and December 31, 2023 - $15.4) | 2,176.0 | | | 2,064.1 | |
Policy loans | 131.3 | | | 128.5 | |
Trading securities | 207.8 | | | 222.7 | |
Investments held by variable interest entities (net of allowance for credit losses: June 30, 2024 - $2.8 and December 31, 2023 - $3.1; amortized cost: June 30, 2024 - $440.6 and December 31, 2023 - $787.6) | 425.5 | | | 768.6 | |
Other invested assets | 1,554.0 | | | 1,353.4 | |
Total investments | 27,230.2 | | | 26,140.4 | |
Cash and cash equivalents - unrestricted | 878.8 | | | 774.5 | |
Cash and cash equivalents held by variable interest entities | 113.3 | | | 114.5 | |
Accrued investment income | 262.5 | | | 251.5 | |
Present value of future profits | 170.4 | | | 180.7 | |
Deferred acquisition costs | 2,047.2 | | | 1,944.4 | |
Reinsurance receivables (net of allowance for credit losses: June 30, 2024 - $3.0 and December 31, 2023 - $3.0) | 3,910.9 | | | 4,040.7 | |
Market risk benefit asset | 84.5 | | | 75.4 | |
Income tax assets, net | 882.8 | | | 936.2 | |
Assets held in separate accounts | 3.2 | | | 3.1 | |
Other assets | 706.4 | | | 641.1 | |
Total assets | $ | 36,290.2 | | | $ | 35,102.5 | |
LIABILITIES AND SHAREHOLDERS' EQUITY | | | |
Liabilities: | | | |
Liabilities for insurance products: | | | |
Policyholder account balances | $ | 16,637.9 | | | $ | 15,667.8 | |
Future policy benefits | 11,479.4 | | | 11,928.2 | |
Market risk benefit liability | 3.2 | | | 7.4 | |
Liability for life insurance policy claims | 59.6 | | | 62.1 | |
Unearned and advanced premiums | 220.9 | | | 218.9 | |
Liabilities related to separate accounts | 3.2 | | | 3.1 | |
Other liabilities | 934.4 | | | 848.8 | |
Investment borrowings | 2,189.0 | | | 2,189.3 | |
Borrowings related to variable interest entities | 501.4 | | | 820.8 | |
Notes payable – direct corporate obligations | 1,832.3 | | | 1,140.5 | |
Total liabilities | 33,861.3 | | | 32,886.9 | |
Commitments and Contingencies | | | |
Shareholders' equity: | | | |
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: June 30, 2024 – 106,513,566; December 31, 2023 – 109,357,540) | 1.1 | | | 1.1 | |
Additional paid-in capital | 1,797.6 | | | 1,891.5 | |
Accumulated other comprehensive loss | (1,464.3) | | | (1,576.8) | |
Retained earnings | 2,094.5 | | | 1,899.8 | |
Total shareholders' equity | 2,428.9 | | | 2,215.6 | |
Total liabilities and shareholders' equity | $ | 36,290.2 | | | $ | 35,102.5 | |
CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS
(Dollars in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended | | Six months ended |
| June 30, | | June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenues: | | | | | | | |
Insurance policy income | $ | 641.5 | | | $ | 628.3 | | | $ | 1,269.9 | | | $ | 1,253.8 | |
Net investment income: | | | | | | | |
General account assets | 351.7 | | | 308.1 | | | 653.6 | | | 600.3 | |
Policyholder and other special-purpose portfolios | 57.4 | | | 91.6 | | | 224.7 | | | 142.4 | |
Investment gains (losses): | | | | | | | |
Realized investment losses | (26.3) | | | (21.8) | | | (36.3) | | | (36.4) | |
Other investment gains (losses) | 9.1 | | | (13.5) | | | 26.9 | | | (13.5) | |
| | | | | | | |
Total investment losses | (17.2) | | | (35.3) | | | (9.4) | | | (49.9) | |
Fee revenue and other income | 32.8 | | | 30.1 | | | 83.9 | | | 82.2 | |
Total revenues | 1,066.2 | | | 1,022.8 | | | 2,222.7 | | | 2,028.8 | |
Benefits and expenses: | | | | | | | |
Insurance policy benefits | 568.8 | | | 565.9 | | | 1,200.2 | | | 1,175.6 | |
Liability for future policy benefits remeasurement (gain) loss | (30.0) | | | 8.3 | | | (36.4) | | | 8.9 | |
Change in fair value of market risk benefits | (0.2) | | | (17.6) | | | (13.9) | | | (2.8) | |
Interest expense | 64.2 | | | 57.6 | | | 124.4 | | | 112.3 | |
Amortization of deferred acquisition costs and present value of future profits | 61.4 | | | 56.0 | | | 121.9 | | | 111.5 | |
| | | | | | | |
| | | | | | | |
Other operating costs and expenses | 251.4 | | | 256.5 | | | 529.7 | | | 528.2 | |
Total benefits and expenses | 915.6 | | | 926.7 | | | 1,925.9 | | | 1,933.7 | |
Income before income taxes | 150.6 | | | 96.1 | | | 296.8 | | | 95.1 | |
| | | | | | | |
Income tax expense | 34.3 | | | 22.4 | | | 68.2 | | | 22.2 | |
| | | | | | | |
Net income | $ | 116.3 | | | $ | 73.7 | | | $ | 228.6 | | | $ | 72.9 | |
Earnings per common share: | | | | | | | |
Basic: | | | | | | | |
Weighted average shares outstanding | 107,731,000 | | | 114,273,000 | | | 108,347,000 | | | 114,409,000 | |
Net income | $ | 1.08 | | | $ | .64 | | | $ | 2.11 | | | $ | .64 | |
Diluted: | | | | | | | |
Weighted average shares outstanding | 109,258,000 | | | 115,650,000 | | | 110,052,000 | | | 116,189,000 | |
Net income | $ | 1.06 | | | $ | .64 | | | $ | 2.08 | | | $ | .63 | |
NOTES
(1)Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and the change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transaction, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes ("net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals. A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 2. Additional information concerning this non-GAAP measure is included in our periodic filings with the Securities and Exchange Commission that are available in the "Investors - SEC Filings" section of CNO's website, CNOinc.com.
(2)Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(3)The calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(4)Measured by new annualized premiums for life and health products, which includes 10% of single premium whole life deposits and 100% of all other premiums (excluding annuities). Sales of third-party products are excluded.
(5)The following summarizes the calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows (dollars in millions):
| | | | | | | | | | | | | | | | | |
| | | Trailing twelve months ended |
| | | 2Q24 | | 2Q23 |
Net operating income | $ | 407.3 | | | $ | 281.7 | |
| | | | | |
Net operating income, excluding significant items | $ | 364.0 | | | $ | 281.2 | |
| | | | | |
Net income | $ | 432.2 | | | $ | 286.8 | |
| | | | | |
Average common equity, excluding accumulated other | | | |
| comprehensive income (loss) and net operating loss | | | |
| carryforwards (a non-GAAP financial measure) | $ | 3,648.4 | | | $ | 3,519.3 | |
| | | | | |
Average common shareholders' equity | $ | 2,171.4 | | | $ | 1,931.5 | |
| | | | | |
Operating return on equity, excluding accumulated other | | | |
| comprehensive income (loss) and net operating loss | | | |
| carryforwards (a non-GAAP financial measure) | 11.2 | % | | 8.0 | % |
| | | | | |
Operating return, excluding significant items, on equity, excluding | | | |
| accumulated other comprehensive income (loss) and net | | | |
| operating loss carryforwards (a non-GAAP financial measure) | 10.0 | % | | 8.0 | % |
| | | | | |
Return on equity | 19.9 | % | | 14.8 | % |
The following summarizes: (i) net operating income; (ii) significant items; (iii) net operating income, excluding significant items; and (iv) net income (loss) (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Net operating | | | | |
| | | | | | Net operating | | income, | | | | |
| | | | | | income, | | excluding | | | | Net |
| | | | | | excluding | | significant | | | | income - |
| | Net operating | | Significant | | significant | | items - trailing | | Net | | trailing |
| | income | | items | | items (a) | | four quarters | | income (loss) | | four quarters |
3Q22 | | $ | 77.9 | | | $ | — | | | $ | 77.9 | | | $ | 360.9 | | | $ | 175.9 | | | $ | 749.8 | |
4Q22 | | 82.9 | | | (0.5) | | (b) | 82.4 | | | 342.5 | | | 38.0 | | | 630.6 | |
1Q23 | | 58.6 | | | — | | | 58.6 | | | 336.6 | | | (0.8) | | | 446.4 | |
2Q23 | | 62.3 | | | — | | | 62.3 | | | 281.2 | | | 73.7 | | | 286.8 | |
3Q23 | | 101.3 | | | (16.9) | | (c) | 84.4 | | | 287.7 | | | 167.3 | | | 278.2 | |
4Q23 | | 133.9 | | | (26.4) | | (d) | 107.5 | | | 312.8 | | | 36.3 | | | 276.5 | |
1Q24 | | 57.5 | | | — | | | 57.5 | | | 311.7 | | | 112.3 | | | 389.6 | |
2Q24 | | 114.6 | | | — | | | 114.6 | | | 364.0 | | | 116.3 | | | 432.2 | |
| | | | | | | | | | | | |
(a) See note (6) for additional information. |
| | | | | | | | | | | | |
(b) Comprised of $.7 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $.2 million. |
| | | | | | | | | | | | |
(c) Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals, net of tax expense of $4.8 million. |
| | | | | | | | | | | | |
(d) Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $7.5 million. |
A reconciliation of pre-tax operating earnings (a non-GAAP financial measure) to net income is as follows (dollars in millions):
| | | | | | | | | | | | | | | | | |
| | | Twelve months ended |
| | | 2Q24 | | 2Q23 |
Pre-tax operating earnings (a non-GAAP financial measure) | $ | 525.3 | | | $ | 365.6 | |
Income tax expense | (118.0) | | | (83.9) | |
Net operating income | 407.3 | | | 281.7 | |
Non-operating items: | | | |
Net realized investment losses from sales, impairments and change in allowance for credit losses | (45.2) | | | (71.9) | |
Net change in market value of investments recognized in earnings | 16.7 | | | (31.9) | |
Changes in fair value of embedded derivative liabilities and market risk benefits | 65.6 | | | 99.5 | |
Fair value changes related to the agent deferred compensation plan | — | | | 12.2 | |
| | | |
Other | (3.9) | | | (2.0) | |
Non-operating income before taxes | 33.2 | | | 5.9 | |
| | | |
Income tax expense on non-operating income | (8.3) | | | (0.8) | |
| | | |
Net non-operating income | 24.9 | | | 5.1 | |
Net income | $ | 432.2 | | | $ | 286.8 | |
| | | | | |
A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 1Q22 | | 2Q22 | | 3Q22 | | 4Q22 |
Consolidated capital, excluding accumulated other comprehensive | | | | | | | |
| income (loss) and net operating loss carryforwards | | | | | | | |
| (a non-GAAP financial measure) | $ | 3,141.7 | | | $ | 3,329.0 | | | $ | 3,510.3 | | | $ | 3,557.1 | |
Net operating loss carryforwards | 238.2 | | | 214.7 | | | 190.9 | | | 169.0 | |
Accumulated other comprehensive loss | (561.5) | | | (1,415.8) | | | (1,837.8) | | | (1,957.3) | |
Common shareholders' equity | $ | 2,818.4 | | | $ | 2,127.9 | | | $ | 1,863.4 | | | $ | 1,768.8 | |
| | | | | | | | | |
| | | 1Q23 | | 2Q23 | | 3Q23 | | 4Q23 |
Consolidated capital, excluding accumulated other comprehensive | | | | | | | |
| income (loss) and net operating loss carryforwards | | | | | | | |
| (a non-GAAP financial measure) | $ | 3,543.8 | | | $ | 3,603.0 | | | $ | 3,744.2 | | | $ | 3,712.8 | |
Net operating loss carryforwards | 152.4 | | | 126.3 | | | 102.6 | | | 79.6 | |
Accumulated other comprehensive loss | (1,664.4) | | | (1,733.5) | | | (1,956.7) | | | (1,576.8) | |
Common shareholders' equity | $ | 2,031.8 | | | $ | 1,995.8 | | | $ | 1,890.1 | | | $ | 2,215.6 | |
| | | | | | | | | |
| | | 1Q24 | | 2Q24 | | | | |
Consolidated capital, excluding accumulated other comprehensive | | | | | | | |
| income (loss) and net operating loss carryforwards | | | | | | | |
| (a non-GAAP financial measure) | $ | 3,536.8 | | | $ | 3,596.7 | | | | | |
Net operating loss carryforwards | 311.2 | | | 296.5 | | | | | |
Accumulated other comprehensive loss | (1,480.3) | | | (1,464.3) | | | | | |
Common shareholders' equity | $ | 2,367.7 | | | $ | 2,428.9 | | | | | |
| | | | | | | | | |
A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows (dollars in millions):
| | | | | | | | | | | | | | | | | |
| | | Trailing four quarter average |
| | | 2Q24 | | 2Q23 |
Consolidated capital, excluding accumulated other comprehensive | | | |
| income (loss) and net operating loss carryforwards | | | |
| (a non-GAAP financial measure) | $ | 3,648.4 | | | $ | 3,519.3 | |
Net operating loss carryforwards | 176.2 | | | 170.7 | |
Accumulated other comprehensive loss | (1,653.2) | | | (1,758.5) | |
Common shareholders' equity | $ | 2,171.4 | | | $ | 1,931.5 | |
(6) The tables below summarize the financial impact of significant items on our net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results (dollars in millions, except per share data).
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 63.6 | | | $ | (12.9) | | (a) | $ | 50.7 | |
Health margin | | 146.4 | | | (22.3) | | (a) | 124.1 | |
Life margin | | 64.6 | | | 1.3 | | (a) | 65.9 | |
Total insurance product margin | | 274.6 | | | (33.9) | | | 240.7 | |
Allocated expenses | | (138.8) | | | — | | | (138.8) | |
Income from insurance products | | 135.8 | | | (33.9) | | | 101.9 | |
Fee income | | 17.8 | | | — | | | 17.8 | |
Investment income not allocated to product lines | | 38.3 | | | — | | | 38.3 | |
Expenses not allocated to product lines | | (19.8) | | | — | | | (19.8) | |
Operating earnings before taxes | | 172.1 | | | (33.9) | | | 138.2 | |
Income tax (expense) benefit on operating income | | (38.2) | | | 7.5 | | | (30.7) | |
Net operating income | | $ | 133.9 | | | $ | (26.4) | | | $ | 107.5 | |
| | | | | | |
Net operating income per diluted share | | $ | 1.18 | | | $ | (0.23) | | | $ | 0.95 | |
___________
(a)Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | September 30, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 57.0 | | | $ | — | | | $ | 57.0 | |
Health margin | | 123.2 | | | — | | | 123.2 | |
Life margin | | 59.8 | | | — | | | 59.8 | |
Total insurance product margin | | 240.0 | | | — | | | 240.0 | |
Allocated expenses | | (153.2) | | | — | | | (153.2) | |
Income from insurance products | | 86.8 | | | — | | | 86.8 | |
Fee income | | (2.9) | | | — | | | (2.9) | |
Investment income not allocated to product lines | | 38.4 | | | — | | | 38.4 | |
Expenses not allocated to product lines | | 7.5 | | | (21.7) | | (a) | (14.2) | |
Operating earnings before taxes | | 129.8 | | | (21.7) | | | 108.1 | |
Income tax (expense) benefit on operating income | | (28.5) | | | 4.8 | | | (23.7) | |
Net operating income | | $ | 101.3 | | | $ | (16.9) | | | $ | 84.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.88 | | | $ | (0.14) | | | $ | 0.74 | |
___________
(a)Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 50.8 | | | $ | 3.2 | | (a) | $ | 54.0 | |
Health margin | | 140.4 | | | (18.3) | | (a) | 122.1 | |
Life margin | | 43.3 | | | 14.4 | | (a) | 57.7 | |
Total insurance product margin | | 234.5 | | | (0.7) | | | 233.8 | |
Allocated expenses | | (149.1) | | | — | | | (149.1) | |
Income from insurance products | | 85.4 | | | (0.7) | | | 84.7 | |
Fee income | | 9.2 | | | — | | | 9.2 | |
Investment income not allocated to product lines | | 25.2 | | | — | | | 25.2 | |
Expenses not allocated to product lines | | (12.8) | | | — | | | (12.8) | |
Operating earnings before taxes | | 107.0 | | | (0.7) | | | 106.3 | |
Income tax (expense) benefit on operating income | | (24.1) | | | 0.2 | | | (23.9) | |
Net operating income | | $ | 82.9 | | | $ | (0.5) | | | $ | 82.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.71 | | | $ | — | | | $ | 0.71 | |
___________
(a)Comprised of $0.7 million of the net favorable impact arising from our comprehensive annual actuarial review.
For further information:
CNO News Media
Valerie Dolenga
Valerie.Dolenga@CNOinc.com
CNO Investor Relations
Adam Auvil
Adam.Auvil@CNOinc.com
Exhibit 99.2
| | | | | | | | | | | | | | | | | |
| | | | | |
| | | | | |
Quarterly Financial Supplement - 2Q2024 | | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
July 29, 2024 | | | | | |
| | | | | |
| | | | | | | | | | | | | | |
Table of Contents | | | | Page |
| | | | |
Consolidated balance sheet | | | | 3 |
Consolidated statement of operations | | | | 4 |
Financial summary | | | | 5 |
Insurance operations | | | | 6 |
Margin from insurance products | | | | 7-9 |
Collected premiums and insurance policy income | | | | 10 |
Health and life new annualized premiums | | | | 11 |
Computation of weighted average shares outstanding | | | | 12 |
Annuities - account value rollforwards | | | | 13 |
Consolidated statutory information of U.S. based insurance subsidiaries | | | | 14 |
Investment income not allocated to product lines and investment income allocated to product lines | | | | 15-18 |
Other investment data | | | | 18 |
Significant items | | | | 19-20 |
Notes | | | | 21-22 |
CNO FINANCIAL GROUP, INC.
CONSOLIDATED BALANCE SHEET
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Mar-23 | | Jun-23 | | Sep-23 | | Dec-23 | | Mar-24 | | Jun-24 | | | | |
Assets | | | | | | | | | | | | | | | |
Investments: | | | | | | | | | | | | | | | |
Fixed maturities, available for sale, at fair value | $ | 21,107.1 | | | $ | 20,959.7 | | | $ | 20,305.2 | | | $ | 21,506.2 | | | $ | 21,648.1 | | | $ | 22,617.9 | | | | | |
Equity securities at fair value | 106.1 | | | 96.4 | | | 95.5 | | | 96.9 | | | 118.4 | | | 117.7 | | | | | |
Mortgage loans | 1,676.1 | | | 1,825.9 | | | 1,971.3 | | | 2,064.1 | | | 2,087.1 | | | 2,176.0 | | | | | |
Policy loans | 123.0 | | | 124.2 | | | 126.4 | | | 128.5 | | | 130.3 | | | 131.3 | | | | | |
Trading securities | 208.1 | | | 218.9 | | | 221.2 | | | 222.7 | | | 222.8 | | | 207.8 | | | | | |
Investments held by variable interest entities | 1,017.9 | | | 948.2 | | | 858.1 | | | 768.6 | | | 533.4 | | | 425.5 | | | | | |
Other invested assets | 1,097.1 | | | 1,176.7 | | | 1,119.9 | | | 1,353.4 | | | 1,471.3 | | | 1,554.0 | | | | | |
Total investments | 25,335.4 | | | 25,350.0 | | | 24,697.6 | | | 26,140.4 | | | 26,211.4 | | | 27,230.2 | | | | | |
Cash and cash equivalents - unrestricted | 425.0 | | | 457.7 | | | 460.8 | | | 774.5 | | | 566.3 | | | 878.8 | | | | | |
Cash and cash equivalents held by variable interest entities | 97.1 | | | 104.2 | | | 122.0 | | | 114.5 | | | 83.5 | | | 113.3 | | | | | |
Accrued investment income | 241.3 | | | 242.1 | | | 252.3 | | | 251.5 | | | 252.0 | | | 262.5 | | | | | |
Present value of future profits | 197.6 | | | 191.8 | | | 186.2 | | | 180.7 | | | 175.5 | | | 170.4 | | | | | |
Deferred acquisition costs | 1,811.3 | | | 1,857.7 | | | 1,897.5 | | | 1,944.4 | | | 1,992.3 | | | 2,047.2 | | | | | |
Reinsurance receivables | 4,189.6 | | | 4,029.2 | | | 4,053.2 | | | 4,040.7 | | | 3,969.0 | | | 3,910.9 | | | | | |
Market risk benefit asset | 57.8 | | | 66.0 | | | 89.3 | | | 75.4 | | | 84.1 | | | 84.5 | | | | | |
Income tax assets, net | 988.1 | | | 1,007.1 | | | 1,039.8 | | | 936.2 | | | 886.1 | | | 882.8 | | | | | |
Assets held in separate accounts | 2.8 | | | 3.0 | | | 2.9 | | | 3.1 | | | 3.3 | | | 3.2 | | | | | |
Other assets | 669.0 | | | 745.1 | | | 705.8 | | | 641.1 | | | 716.2 | | | 706.4 | | | | | |
Total assets | $ | 34,015.0 | | | $ | 34,053.9 | | | $ | 33,507.4 | | | $ | 35,102.5 | | | $ | 34,939.7 | | | $ | 36,290.2 | | | | | |
Liabilities | | | | | | | | | | | | | | | |
Liabilities for insurance products: | | | | | | | | | | | | | | | |
Policyholder account balances | $ | 15,302.9 | | | $ | 15,387.7 | | | $ | 15,481.8 | | | $ | 15,667.8 | | | $ | 15,736.7 | | | $ | 16,637.9 | | | | | |
Future policy benefits | 11,623.3 | | | 11,479.6 | | | 10,829.9 | | | 11,928.2 | | | 11,736.5 | | | 11,479.4 | | | | | |
Market risk benefit liability | 17.6 | | | 10.5 | | | 3.1 | | | 7.4 | | | 3.8 | | | 3.2 | | | | | |
Liability for life insurance policy claims | 67.6 | | | 64.6 | | | 60.8 | | | 62.1 | | | 65.1 | | | 59.6 | | | | | |
Unearned and advanced premiums | 243.5 | | | 233.6 | | | 221.2 | | | 218.9 | | | 226.0 | | | 220.9 | | | | | |
Liabilities related to separate accounts | 2.8 | | | 3.0 | | | 2.9 | | | 3.1 | | | 3.3 | | | 3.2 | | | | | |
Other liabilities | 681.3 | | | 898.9 | | | 869.6 | | | 848.8 | | | 905.0 | | | 934.4 | | | | | |
Investment borrowings | 1,839.6 | | | 1,839.5 | | | 2,089.4 | | | 2,189.3 | | | 2,189.1 | | | 2,189.0 | | | | | |
Borrowings related to variable interest entities | 1,065.4 | | | 1,001.0 | | | 918.5 | | | 820.8 | | | 565.5 | | | 501.4 | | | | | |
Notes payable - direct corporate obligations | 1,139.2 | | | 1,139.7 | | | 1,140.1 | | | 1,140.5 | | | 1,141.0 | | | 1,832.3 | | | | | |
Total liabilities | 31,983.2 | | | 32,058.1 | | | 31,617.3 | | | 32,886.9 | | | 32,572.0 | | | 33,861.3 | | | | | |
Shareholders' equity | | | | | | | | | | | | | | | |
Common stock | 1.1 | | | 1.1 | | | 1.1 | | | 1.1 | | | 1.1 | | | 1.1 | | | | | |
Additional paid-in capital | 2,021.1 | | | 1,997.9 | | | 1,965.3 | | | 1,891.5 | | | 1,851.2 | | | 1,797.6 | | | | | |
Retained earnings | 1,674.0 | | | 1,730.3 | | | 1,880.4 | | | 1,899.8 | | | 1,995.7 | | | 2,094.5 | | | | | |
Total shareholders' equity before accumulated other comprehensive loss | 3,696.2 | | | 3,729.3 | | | 3,846.8 | | | 3,792.4 | | | 3,848.0 | | | 3,893.2 | | | | | |
Accumulated other comprehensive loss | (1,664.4) | | | (1,733.5) | | | (1,956.7) | | | (1,576.8) | | | (1,480.3) | | | (1,464.3) | | | | | |
Total shareholders' equity | 2,031.8 | | | 1,995.8 | | | 1,890.1 | | | 2,215.6 | | | 2,367.7 | | | 2,428.9 | | | | | |
Total liabilities and shareholders' equity | $ | 34,015.0 | | | $ | 34,053.9 | | | $ | 33,507.4 | | | $ | 35,102.5 | | | $ | 34,939.7 | | | $ | 36,290.2 | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Mar-23 | | Jun-23 | | Sep-23 | | Dec-23 | | Mar-24 | | Jun-24 | | | | |
| | | | | | | | | | | | | | | |
Book value per common share | $ | 17.68 | | | $ | 17.56 | | | $ | 16.85 | | | $ | 20.26 | | | $ | 21.81 | | | $ | 22.80 | | | | | |
| | | | | | | | | | | | | | | |
Book value per common share, excluding accumulated other comprehensive loss (1) (2) | $ | 32.17 | | | $ | 32.81 | | | $ | 34.30 | | | $ | 34.68 | | | $ | 35.44 | | | $ | 36.55 | | | | | |
| | | | | | | | | | | | | | | |
Book value per diluted share (1) (3) | $ | 31.82 | | | $ | 32.34 | | | $ | 33.75 | | | $ | 33.94 | | | $ | 34.97 | | | $ | 36.00 | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Revenues | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 625.5 | | | $ | 628.3 | | | $ | 626.0 | | | $ | 625.7 | | | $ | 2,505.5 | | | $ | 628.4 | | | $ | 641.5 | | | | | | | |
Net investment income: | | | | | | | | | | | | | | | | | | | |
General account assets | 292.2 | | | 308.1 | | | 324.8 | | | 325.1 | | | 1,250.2 | | | 301.9 | | | 351.7 | | | | | | | |
Policyholder and other special-purpose portfolios | 50.8 | | | 91.6 | | | (33.0) | | | 140.1 | | | 249.5 | | | 167.3 | | | 57.4 | | | | | | | |
Investment gains (losses): | | | | | | | | | | | | | | | | | | | |
Realized investment losses | (14.6) | | | (21.8) | | | (21.6) | | | (11.3) | | | (69.3) | | | (10.0) | | | (26.3) | | | | | | | |
Other investment gains (losses) | — | | | (13.5) | | | (7.7) | | | 21.5 | | | 0.3 | | | 17.8 | | | 9.1 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Total investment gains (losses) | (14.6) | | | (35.3) | | | (29.3) | | | 10.2 | | | (69.0) | | | 7.8 | | | (17.2) | | | | | | | |
Fee revenue and other income | 52.1 | | | 30.1 | | | 59.0 | | | 69.4 | | | 210.6 | | | 51.1 | | | 32.8 | | | | | | | |
Total revenues | 1,006.0 | | | 1,022.8 | | | 947.5 | | | 1,170.5 | | | 4,146.8 | | | 1,156.5 | | | 1,066.2 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Benefits and expenses | | | | | | | | | | | | | | | | | | | |
Insurance policy benefits | 609.7 | | | 565.9 | | | 399.1 | | | 743.5 | | | 2,318.2 | | | 631.4 | | | 568.8 | | | | | | | |
Liability for future policy benefits remeasurement (gain) loss | 0.6 | | | 8.3 | | | (0.1) | | | (30.0) | | | (21.2) | | | (6.4) | | | (30.0) | | | | | | | |
Change in fair value of market risk benefits | 14.8 | | | (17.6) | | | (33.8) | | | 15.3 | | | (21.3) | | | (13.7) | | | (0.2) | | | | | | | |
Interest expense | 54.7 | | | 57.6 | | | 62.6 | | | 63.7 | | | 238.6 | | | 60.2 | | | 64.2 | | | | | | | |
Amortization of deferred acquisition costs and present value of future profits | 55.5 | | | 56.0 | | | 57.0 | | | 58.9 | | | 227.4 | | | 60.5 | | | 61.4 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Other operating costs and expenses | 271.7 | | | 256.5 | | | 247.1 | | | 273.0 | | | 1,048.3 | | | 278.3 | | | 251.4 | | | | | | | |
Total benefits and expenses | 1,007.0 | | | 926.7 | | | 731.9 | | | 1,124.4 | | | 3,790.0 | | | 1,010.3 | | | 915.6 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Income (loss) before income taxes | (1.0) | | | 96.1 | | | 215.6 | | | 46.1 | | | 356.8 | | | 146.2 | | | 150.6 | | | | | | | |
Income tax expense (benefit) on period income (loss) | (0.2) | | | 22.4 | | | 48.3 | | | 9.8 | | | 80.3 | | | 33.9 | | | 34.3 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Net income (loss) | $ | (0.8) | | | $ | 73.7 | | | $ | 167.3 | | | $ | 36.3 | | | $ | 276.5 | | | $ | 112.3 | | | $ | 116.3 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
FINANCIAL SUMMARY
(Dollars in millions, except per share data)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Insurance product margin (4) | | | | | | | | | | | | | | | | | | | |
Annuity margin | $ | 57.3 | | | $ | 57.1 | | | $ | 57.0 | | | $ | 63.6 | | | $ | 235.0 | | | $ | 52.0 | | | $ | 76.1 | | | | | | | |
Health margin | 116.5 | | | 108.2 | | | 123.2 | | | 146.4 | | | 494.3 | | | 123.0 | | | 135.9 | | | | | | | |
Life margin | 47.4 | | | 57.9 | | | 59.8 | | | 64.6 | | | 229.7 | | | 54.6 | | | 63.1 | | | | | | | |
Total insurance product margin | 221.2 | | | 223.2 | | | 240.0 | | | 274.6 | | | 959.0 | | | 229.6 | | | 275.1 | | | | | | | |
Allocated expenses | (157.5) | | | (149.5) | | | (153.2) | | | (138.8) | | | (599.0) | | | (161.6) | | | (154.6) | | | | | | | |
Income from insurance products (8) | 63.7 | | | 73.7 | | | 86.8 | | | 135.8 | | | 360.0 | | | 68.0 | | | 120.5 | | | | | | | |
Fee income | 15.5 | | | 0.6 | | | (2.9) | | | 17.8 | | | 31.0 | | | 11.3 | | | 0.8 | | | | | | | |
Investment income not allocated to product lines (9) | 15.5 | | | 28.0 | | | 38.4 | | | 38.3 | | | 120.2 | | | 12.3 | | | 44.8 | | | | | | | |
Expenses not allocated to product lines | (18.3) | | | (21.1) | | | 7.5 | | | (19.8) | | | (51.7) | | | (16.8) | | | (17.5) | | | | | | | |
Operating earnings before taxes | 76.4 | | | 81.2 | | | 129.8 | | | 172.1 | | | 459.5 | | | 74.8 | | | 148.6 | | | | | | | |
Income tax expense on operating income | (17.8) | | | (18.9) | | | (28.5) | | | (38.2) | | | (103.4) | | | (17.3) | | | (34.0) | | | | | | | |
Net operating income (10) | 58.6 | | | 62.3 | | | 101.3 | | | 133.9 | | | 356.1 | | | 57.5 | | | 114.6 | | | | | | | |
Net realized investment gains (losses) from sales, impairments and change in allowance for credit losses | (12.7) | | | (31.3) | | | (20.1) | | | 1.4 | | | (62.7) | | | (4.6) | | | (21.9) | | | | | | | |
Net change in market value of investments recognized in earnings | (1.9) | | | (4.0) | | | (9.2) | | | 8.8 | | | (6.3) | | | 12.4 | | | 4.7 | | | | | | | |
Fair value changes related to agent deferred compensation plan | — | | | — | | | 6.8 | | | (10.3) | | | (3.5) | | | — | | | 3.5 | | | | | | | |
Changes in fair value of embedded derivative liabilities and market risk benefits | (65.1) | | | 50.4 | | | 109.4 | | | (124.6) | | | (29.9) | | | 64.0 | | | 16.8 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Other | 2.3 | | | (0.2) | | | (1.1) | | | (1.3) | | | (0.3) | | | (0.4) | | | (1.1) | | | | | | | |
Net non-operating income (loss) before taxes | (77.4) | | | 14.9 | | | 85.8 | | | (126.0) | | | (102.7) | | | 71.4 | | | 2.0 | | | | | | | |
Income tax (expense) benefit on non-operating income (loss) | 18.0 | | | (3.5) | | | (19.8) | | | 28.4 | | | 23.1 | | | (16.6) | | | (0.3) | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Net non-operating income (loss) | (59.4) | | | 11.4 | | | 66.0 | | | (97.6) | | | (79.6) | | | 54.8 | | | 1.7 | | | | | | | |
Net income (loss) | $ | (0.8) | | | $ | 73.7 | | | $ | 167.3 | | | $ | 36.3 | | | $ | 276.5 | | | $ | 112.3 | | | $ | 116.3 | | | | | | | |
Per diluted share | | | | | | | | | | | | | | | | | | | |
Net operating income | $ | 0.51 | | | $ | 0.54 | | | $ | 0.88 | | | $ | 1.18 | | | $ | 3.09 | | | $ | 0.52 | | | $ | 1.05 | | | | | | | |
Net non-operating income (loss) | (0.52) | | | 0.10 | | | 0.58 | | | (0.86) | | | (0.69) | | | 0.49 | | | 0.01 | | | | | | | |
Net income (loss) | $ | (0.01) | | | $ | 0.64 | | | $ | 1.46 | | | $ | 0.32 | | | $ | 2.40 | | | $ | 1.01 | | | $ | 1.06 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Insurance Operations
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Insurance product margin (4) | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 5.1 | | | $ | 8.1 | | | $ | 7.2 | | | $ | 8.0 | | | $ | 28.4 | | | $ | 7.3 | | | $ | 9.3 | | | | | | | |
Net investment income (5) (6) | 125.4 | | | 127.7 | | | 131.0 | | | 132.2 | | | 516.3 | | | 134.5 | | | 140.5 | | | | | | | |
Insurance policy benefits | (8.7) | | | (10.6) | | | (9.8) | | | 0.1 | | | (29.0) | | | (11.3) | | | 8.4 | | | | | | | |
Interest credited (6) | (48.1) | | | (50.6) | | | (53.4) | | | (57.3) | | | (209.4) | | | (58.3) | | | (61.2) | | | | | | | |
Amortization and non-deferred commissions | (16.4) | | | (17.5) | | | (18.0) | | | (19.4) | | | (71.3) | | | (20.2) | | | (20.9) | | | | | | | |
Annuity margin | 57.3 | | | 57.1 | | | 57.0 | | | 63.6 | | | 235.0 | | | 52.0 | | | 76.1 | | | | | | | |
Health: | | | | | | | | | | | | | | | | | | | |
Insurance policy income | 401.4 | | | 397.1 | | | 397.8 | | | 398.3 | | | 1,594.6 | | | 398.4 | | | 403.6 | | | | | | | |
Net investment income (5) | 74.0 | | | 74.3 | | | 74.2 | | | 74.2 | | | 296.7 | | | 74.3 | | | 75.1 | | | | | | | |
Insurance policy benefits | (318.1) | | | (322.7) | | | (308.5) | | | (285.6) | | | (1,234.9) | | | (308.5) | | | (302.3) | | | | | | | |
Amortization and non-deferred commissions | (40.8) | | | (40.5) | | | (40.3) | | | (40.5) | | | (162.1) | | | (41.2) | | | (40.5) | | | | | | | |
Health margin | 116.5 | | | 108.2 | | | 123.2 | | | 146.4 | | | 494.3 | | | 123.0 | | | 135.9 | | | | | | | |
Life: | | | | | | | | | | | | | | | | | | | |
Insurance policy income | 219.0 | | | 223.1 | | | 221.0 | | | 219.4 | | | 882.5 | | | 222.7 | | | 228.6 | | | | | | | |
Net investment income (5) (7) | 36.3 | | | 36.1 | | | 36.3 | | | 36.1 | | | 144.8 | | | 36.5 | | | 36.7 | | | | | | | |
Insurance policy benefits | (147.2) | | | (142.8) | | | (140.7) | | | (139.3) | | | (570.0) | | | (144.0) | | | (144.6) | | | | | | | |
Interest credited (7) | (12.1) | | | (12.2) | | | (12.1) | | | (12.9) | | | (49.3) | | | (12.5) | | | (12.4) | | | | | | | |
Amortization and non-deferred commissions | (19.9) | | | (20.8) | | | (22.1) | | | (23.0) | | | (85.8) | | | (23.5) | | | (24.3) | | | | | | | |
Advertising expense | (28.7) | | | (25.5) | | | (22.6) | | | (15.7) | | | (92.5) | | | (24.6) | | | (20.9) | | | | | | | |
Life margin | 47.4 | | | 57.9 | | | 59.8 | | | 64.6 | | | 229.7 | | | 54.6 | | | 63.1 | | | | | | | |
Total insurance product margin | 221.2 | | | 223.2 | | | 240.0 | | | 274.6 | | | 959.0 | | | 229.6 | | | 275.1 | | | | | | | |
Allocated expenses: | | | | | | | | | | | | | | | | | | | |
Branch office expenses | (19.8) | | | (15.9) | | | (16.3) | | | (12.9) | | | (64.9) | | | (19.8) | | | (16.2) | | | | | | | |
Other allocated expenses | (137.7) | | | (133.6) | | | (136.9) | | | (125.9) | | | (534.1) | | | (141.8) | | | (138.4) | | | | | | | |
Income from insurance products (8) | 63.7 | | | 73.7 | | | 86.8 | | | 135.8 | | | 360.0 | | | 68.0 | | | 120.5 | | | | | | | |
Fee income | 15.5 | | | 0.6 | | | (2.9) | | | 17.8 | | | 31.0 | | | 11.3 | | | 0.8 | | | | | | | |
Investment income not allocated to product lines (9) | 15.5 | | | 28.0 | | | 38.4 | | | 38.3 | | | 120.2 | | | 12.3 | | | 44.8 | | | | | | | |
Expenses not allocated to product lines | (18.3) | | | (21.1) | | | 7.5 | | | (19.8) | | | (51.7) | | | (16.8) | | | (17.5) | | | | | | | |
Operating earnings before taxes | 76.4 | | | 81.2 | | | 129.8 | | | 172.1 | | | 459.5 | | | 74.8 | | | 148.6 | | | | | | | |
Income tax expense on operating income | (17.8) | | | (18.9) | | | (28.5) | | | (38.2) | | | (103.4) | | | (17.3) | | | (34.0) | | | | | | | |
Net operating income (10) | $ | 58.6 | | | $ | 62.3 | | | $ | 101.3 | | | $ | 133.9 | | | $ | 356.1 | | | $ | 57.5 | | | $ | 114.6 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Margin from Annuity Products
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Annuity margin (4): | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 3.6 | | | $ | 5.5 | | | $ | 5.1 | | | $ | 5.5 | | | $ | 19.7 | | | $ | 6.0 | | | $ | 7.2 | | | | | | | |
Net investment income (5) (6) | 98.8 | | | 101.2 | | | 104.4 | | | 105.9 | | | 410.3 | | | 108.4 | | | 113.8 | | | | | | | |
Insurance policy benefits | (4.1) | | | (4.2) | | | (4.3) | | | 2.5 | | | (10.1) | | | (5.8) | | | (2.6) | | | | | | | |
Interest credited (6) | (36.4) | | | (38.9) | | | (41.5) | | | (45.1) | | | (161.9) | | | (46.7) | | | (49.4) | | | | | | | |
Amortization and non-deferred commissions | (15.4) | | | (16.0) | | | (16.5) | | | (17.9) | | | (65.8) | | | (18.5) | | | (19.1) | | | | | | | |
Margin from fixed indexed annuities | $ | 46.5 | | | $ | 47.6 | | | $ | 47.2 | | | $ | 50.9 | | | $ | 192.2 | | | $ | 43.4 | | | $ | 49.9 | | | | | | | |
Average net insurance liabilities (11) | $ | 9,183.8 | | | $ | 9,276.0 | | | $ | 9,381.0 | | | $ | 9,508.7 | | | $ | 9,337.3 | | | $ | 9,636.3 | | | $ | 9,758.1 | | | | | | | |
Margin/average net insurance liabilities (12) | 2.03 | % | | 2.05 | % | | 2.01 | % | | 2.14 | % | | 2.06 | % | | 1.80 | % | | 2.05 | % | | | | | | |
Fixed interest annuities | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 0.3 | | | $ | 0.2 | | | $ | 0.3 | | | $ | 0.2 | | | $ | 1.0 | | | $ | 0.1 | | | $ | 0.4 | | | | | | | |
Net investment income (5) | 20.9 | | | 20.9 | | | 21.0 | | | 20.8 | | | 83.6 | | | 20.6 | | | 21.1 | | | | | | | |
Insurance policy benefits | (0.1) | | | — | | | (0.1) | | | (0.3) | | | (0.5) | | | (0.4) | | | 0.1 | | | | | | | |
Interest credited | (11.1) | | | (11.1) | | | (11.4) | | | (11.6) | | | (45.2) | | | (11.1) | | | (11.3) | | | | | | | |
Amortization and non-deferred commissions | (0.9) | | | (1.3) | | | (1.4) | | | (1.4) | | | (5.0) | | | (1.6) | | | (1.6) | | | | | | | |
Margin from fixed interest annuities | $ | 9.1 | | | $ | 8.7 | | | $ | 8.4 | | | $ | 7.7 | | | $ | 33.9 | | | $ | 7.6 | | | $ | 8.7 | | | | | | | |
Average net insurance liabilities (11) | $ | 1,630.9 | | | $ | 1,613.1 | | | $ | 1,603.0 | | | $ | 1,600.9 | | | $ | 1,612.0 | | | $ | 1,588.0 | | | $ | 1,569.4 | | | | | | | |
Margin/average net insurance liabilities (12) | 2.23 | % | | 2.16 | % | | 2.10 | % | | 1.92 | % | | 2.10 | % | | 1.91 | % | | 2.22 | % | | | | | | |
Other annuities | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 1.2 | | | $ | 2.4 | | | $ | 1.8 | | | $ | 2.3 | | | $ | 7.7 | | | $ | 1.2 | | | $ | 1.7 | | | | | | | |
Net investment income (5) | 5.7 | | | 5.6 | | | 5.6 | | | 5.5 | | | 22.4 | | | 5.5 | | | 5.6 | | | | | | | |
Insurance policy benefits | (4.5) | | | (6.4) | | | (5.4) | | | (2.1) | | | (18.4) | | | (5.1) | | | 10.9 | | | | | | | |
Interest credited | (0.6) | | | (0.6) | | | (0.5) | | | (0.6) | | | (2.3) | | | (0.5) | | | (0.5) | | | | | | | |
Amortization and non-deferred commissions | (0.1) | | | (0.2) | | | (0.1) | | | (0.1) | | | (0.5) | | | (0.1) | | | (0.2) | | | | | | | |
Margin from other annuities | $ | 1.7 | | | $ | 0.8 | | | $ | 1.4 | | | $ | 5.0 | | | $ | 8.9 | | | $ | 1.0 | | | $ | 17.5 | | | | | | | |
Average net insurance liabilities (11) | $ | 469.5 | | | $ | 462.5 | | | $ | 455.6 | | | $ | 447.5 | | | $ | 458.8 | | | $ | 439.9 | | | $ | 426.4 | | | | | | | |
Margin/average net insurance liabilities (12) | 1.45 | % | | 0.69 | % | | 1.23 | % | | 4.47 | % | | 1.94 | % | | 0.91 | % | | 16.42 | % | | | | | | |
Total annuity margin | $ | 57.3 | | | $ | 57.1 | | | $ | 57.0 | | | $ | 63.6 | | | $ | 235.0 | | | $ | 52.0 | | | $ | 76.1 | | | | | | | |
Average net insurance liabilities (11) | $ | 11,284.2 | | | $ | 11,351.6 | | | $ | 11,439.6 | | | $ | 11,557.1 | | | $ | 11,408.1 | | | $ | 11,664.2 | | | $ | 11,753.9 | | | | | | | |
Margin/average net insurance liabilities (12) | 2.03 | % | | 2.01 | % | | 1.99 | % | | 2.20 | % | | 2.06 | % | | 1.78 | % | | 2.59 | % | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Margin from Health Products
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Health margin (4): | | | | | | | | | | | | | | | | | | | |
Supplemental health | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 179.0 | | | $ | 176.2 | | | $ | 177.9 | | | $ | 178.1 | | | $ | 711.2 | | | $ | 179.7 | | | $ | 180.1 | | | | | | | |
Net investment income (5) | 38.6 | | | 38.9 | | | 39.0 | | | 38.8 | | | 155.3 | | | 39.0 | | | 39.4 | | | | | | | |
Insurance policy benefits | (128.2) | | | (128.9) | | | (128.0) | | | (81.0) | | | (466.1) | | | (125.8) | | | (127.4) | | | | | | | |
Amortization and non-deferred commissions | (26.1) | | | (26.3) | | | (26.1) | | | (27.5) | | | (106.0) | | | (27.5) | | | (27.0) | | | | | | | |
Margin from supplemental health | $ | 63.3 | | | $ | 59.9 | | | $ | 62.8 | | | $ | 108.4 | | | $ | 294.4 | | | $ | 65.4 | | | $ | 65.1 | | | | | | | |
Margin/insurance policy income | 35 | % | | 34 | % | | 35 | % | | 61 | % | | 41 | % | | 36 | % | | 36 | % | | | | | | |
Medicare supplement | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 156.5 | | | $ | 155.3 | | | $ | 154.2 | | | $ | 153.9 | | | $ | 619.9 | | | $ | 151.7 | | | $ | 155.8 | | | | | | | |
Net investment income (5) | 1.3 | | | 1.2 | | | 1.1 | | | 1.3 | | | 4.9 | | | 1.4 | | | 1.3 | | | | | | | |
Insurance policy benefits | (120.5) | | | (113.4) | | | (107.4) | | | (123.4) | | | (464.7) | | | (116.4) | | | (111.5) | | | | | | | |
Amortization and non-deferred commissions | (11.2) | | | (10.8) | | | (10.7) | | | (10.5) | | | (43.2) | | | (10.2) | | | (10.1) | | | | | | | |
Margin from Medicare supplement | $ | 26.1 | | | $ | 32.3 | | | $ | 37.2 | | | $ | 21.3 | | | $ | 116.9 | | | $ | 26.5 | | | $ | 35.5 | | | | | | | |
Margin/insurance policy income | 17 | % | | 21 | % | | 24 | % | | 14 | % | | 19 | % | | 17 | % | | 23 | % | | | | | | |
Long-term care | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 65.9 | | | $ | 65.6 | | | $ | 65.7 | | | $ | 66.3 | | | $ | 263.5 | | | $ | 67.0 | | | $ | 67.7 | | | | | | | |
Net investment income (5) | 34.1 | | | 34.2 | | | 34.1 | | | 34.1 | | | 136.5 | | | 33.9 | | | 34.4 | | | | | | | |
Insurance policy benefits | (69.4) | | | (80.4) | | | (73.1) | | | (81.2) | | | (304.1) | | | (66.3) | | | (63.4) | | | | | | | |
Amortization and non-deferred commissions | (3.5) | | | (3.4) | | | (3.5) | | | (2.5) | | | (12.9) | | | (3.5) | | | (3.4) | | | | | | | |
Margin from long-term care | $ | 27.1 | | | $ | 16.0 | | | $ | 23.2 | | | $ | 16.7 | | | $ | 83.0 | | | $ | 31.1 | | | $ | 35.3 | | | | | | | |
Margin/insurance policy income | 41 | % | | 24 | % | | 35 | % | | 25 | % | | 31 | % | | 46 | % | | 52 | % | | | | | | |
Total health margin | $ | 116.5 | | | $ | 108.2 | | | $ | 123.2 | | | $ | 146.4 | | | $ | 494.3 | | | $ | 123.0 | | | $ | 135.9 | | | | | | | |
Margin/insurance policy income | 29 | % | | 27 | % | | 31 | % | | 37 | % | | 31 | % | | 31 | % | | 34 | % | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Margin from Life Products
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Life margin (4): | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 44.5 | | | $ | 45.3 | | | $ | 45.1 | | | $ | 46.2 | | | $ | 181.1 | | | $ | 46.6 | | | $ | 46.9 | | | | | | | |
Net investment income (5) (7) | 13.1 | | | 12.7 | | | 12.9 | | | 12.8 | | | 51.5 | | | 13.2 | | | 13.2 | | | | | | | |
Insurance policy benefits | (18.2) | | | (17.1) | | | (18.1) | | | (12.3) | | | (65.7) | | | (19.9) | | | (18.6) | | | | | | | |
Interest credited (7) | (12.0) | | | (12.0) | | | (11.9) | | | (12.8) | | | (48.7) | | | (12.3) | | | (12.3) | | | | | | | |
Amortization and non-deferred commissions | (4.6) | | | (4.8) | | | (5.1) | | | (5.0) | | | (19.5) | | | (5.1) | | | (5.3) | | | | | | | |
Margin from interest sensitive life | $ | 22.8 | | | $ | 24.1 | | | $ | 22.9 | | | $ | 28.9 | | | $ | 98.7 | | | $ | 22.5 | | | $ | 23.9 | | | | | | | |
Average net insurance liabilities (11) | $ | 1,032.0 | | | $ | 1,035.4 | | | $ | 1,039.6 | | | $ | 1,045.8 | | | $ | 1,038.2 | | | $ | 1,056.1 | | | $ | 1,063.0 | | | | | | | |
Interest margin | $ | 1.1 | | | $ | 0.7 | | | $ | 1.0 | | | $ | — | | | $ | 2.8 | | | $ | 0.9 | | | $ | 0.9 | | | | | | | |
Interest margin/average net insurance liabilities (12) | 0.43 | % | | 0.27 | % | | 0.38 | % | | — | % | | 0.27 | % | | 0.34 | % | | 0.34 | % | | | | | | |
Underwriting margin | $ | 21.7 | | | $ | 23.4 | | | $ | 21.9 | | | $ | 28.9 | | | $ | 95.9 | | | $ | 21.6 | | | $ | 23.0 | | | | | | | |
Underwriting margin/insurance policy income | 49 | % | | 52 | % | | 49 | % | | 63 | % | | 53 | % | | 46 | % | | 49 | % | | | | | | |
Traditional life | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 174.5 | | | $ | 177.8 | | | $ | 175.9 | | | $ | 173.2 | | | $ | 701.4 | | | $ | 176.1 | | | $ | 181.7 | | | | | | | |
Net investment income (5) | 23.2 | | | 23.4 | | | 23.4 | | | 23.3 | | | 93.3 | | | 23.3 | | | 23.5 | | | | | | | |
Insurance policy benefits | (129.0) | | | (125.7) | | | (122.6) | | | (127.0) | | | (504.3) | | | (124.1) | | | (126.0) | | | | | | | |
Interest credited | (0.1) | | | (0.2) | | | (0.2) | | | (0.1) | | | (0.6) | | | (0.2) | | | (0.1) | | | | | | | |
Amortization and non-deferred commissions | (15.3) | | | (16.0) | | | (17.0) | | | (18.0) | | | (66.3) | | | (18.4) | | | (19.0) | | | | | | | |
Advertising expense | (28.7) | | | (25.5) | | | (22.6) | | | (15.7) | | | (92.5) | | | (24.6) | | | (20.9) | | | | | | | |
Margin from traditional life | $ | 24.6 | | | $ | 33.8 | | | $ | 36.9 | | | $ | 35.7 | | | $ | 131.0 | | | $ | 32.1 | | | $ | 39.2 | | | | | | | |
Margin/insurance policy income | 14 | % | | 19 | % | | 21 | % | | 21 | % | | 19 | % | | 18 | % | | 22 | % | | | | | | |
Margin excluding advertising expense/insurance policy income | 31 | % | | 33 | % | | 34 | % | | 30 | % | | 32 | % | | 32 | % | | 33 | % | | | | | | |
Total life margin | $ | 47.4 | | | $ | 57.9 | | | $ | 59.8 | | | $ | 64.6 | | | $ | 229.7 | | | $ | 54.6 | | | $ | 63.1 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Collected Premiums and Insurance Policy Income
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Collected premiums: | | | | | | | | | | | | | | | | | | | |
Annuity products | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | $ | 323.3 | | | $ | 351.6 | | | $ | 321.8 | | | $ | 377.2 | | | $ | 1,373.9 | | | $ | 345.5 | | | $ | 388.5 | | | | | | | |
Fixed interest annuities | 46.1 | | | 46.6 | | | 48.9 | | | 58.1 | | | 199.7 | | | 45.9 | | | 49.1 | | | | | | | |
Other annuities | 1.5 | | | 3.6 | | | 1.5 | | | 3.0 | | | 9.6 | | | 1.9 | | | 1.5 | | | | | | | |
Total annuity collected premiums | 370.9 | | | 401.8 | | | 372.2 | | | 438.3 | | | 1,583.2 | | | 393.3 | | | 439.1 | | | | | | | |
Health products | | | | | | | | | | | | | | | | | | | |
Supplemental health | 180.0 | | | 175.8 | | | 175.6 | | | 175.2 | | | 706.6 | | | 181.4 | | | 179.8 | | | | | | | |
Medicare supplement | 158.4 | | | 148.4 | | | 146.6 | | | 156.0 | | | 609.4 | | | 155.7 | | | 152.4 | | | | | | | |
Long-term care | 66.5 | | | 65.1 | | | 63.9 | | | 66.3 | | | 261.8 | | | 67.7 | | | 67.9 | | | | | | | |
Total health collected premiums | 404.9 | | | 389.3 | | | 386.1 | | | 397.5 | | | 1,577.8 | | | 404.8 | | | 400.1 | | | | | | | |
Life products | | | | | | | | | | | | | | | | | | | |
Interest-sensitive life | 58.2 | | | 60.3 | | | 58.3 | | | 60.2 | | | 237.0 | | | 60.5 | | | 61.3 | | | | | | | |
Traditional life | 176.4 | | | 176.3 | | | 175.2 | | | 172.1 | | | 700.0 | | | 176.8 | | | 181.1 | | | | | | | |
Total life collected premiums | 234.6 | | | 236.6 | | | 233.5 | | | 232.3 | | | 937.0 | | | 237.3 | | | 242.4 | | | | | | | |
Total collected premiums | $ | 1,010.4 | | | $ | 1,027.7 | | | $ | 991.8 | | | $ | 1,068.1 | | | $ | 4,098.0 | | | $ | 1,035.4 | | | $ | 1,081.6 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Insurance policy income: | | | | | | | | | | | | | | | | | | | |
Annuity products | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | $ | 3.6 | | | $ | 5.5 | | | $ | 5.1 | | | $ | 5.5 | | | $ | 19.7 | | | $ | 6.0 | | | $ | 7.2 | | | | | | | |
Fixed interest annuities | 0.3 | | | 0.2 | | | 0.3 | | | 0.2 | | | 1.0 | | | 0.1 | | | 0.4 | | | | | | | |
Other annuities | 1.2 | | | 2.4 | | | 1.8 | | | 2.3 | | | 7.7 | | | 1.2 | | | 1.7 | | | | | | | |
Total annuity insurance policy income | 5.1 | | | 8.1 | | | 7.2 | | | 8.0 | | | 28.4 | | | 7.3 | | | 9.3 | | | | | | | |
Health products | | | | | | | | | | | | | | | | | | | |
Supplemental health | 179.0 | | | 176.2 | | | 178.0 | | | 178.1 | | | 711.3 | | | 179.7 | | | 180.1 | | | | | | | |
Medicare supplement | 156.5 | | | 155.3 | | | 154.1 | | | 153.9 | | | 619.8 | | | 151.7 | | | 155.8 | | | | | | | |
Long-term care | 65.9 | | | 65.6 | | | 65.7 | | | 66.3 | | | 263.5 | | | 67.0 | | | 67.7 | | | | | | | |
Total health insurance policy income | 401.4 | | | 397.1 | | | 397.8 | | | 398.3 | | | 1,594.6 | | | 398.4 | | | 403.6 | | | | | | | |
Life products | | | | | | | | | | | | | | | | | | | |
Interest-sensitive life | 44.5 | | | 45.3 | | | 45.1 | | | 46.2 | | | 181.1 | | | 46.6 | | | 46.9 | | | | | | | |
Traditional life | 174.5 | | | 177.8 | | | 175.9 | | | 173.2 | | | 701.4 | | | 176.1 | | | 181.7 | | | | | | | |
Total life insurance policy income | 219.0 | | | 223.1 | | | 221.0 | | | 219.4 | | | 882.5 | | | 222.7 | | | 228.6 | | | | | | | |
Total insurance policy income | $ | 625.5 | | | $ | 628.3 | | | $ | 626.0 | | | $ | 625.7 | | | $ | 2,505.5 | | | $ | 628.4 | | | $ | 641.5 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Health and Life
New Annualized Premiums ("NAP")
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Consumer Division | | | | | | | | | | | | | | | | | | | |
Health products: | | | | | | | | | | | | | | | | | | | |
Supplemental health | $ | 17.4 | | | $ | 18.7 | | | $ | 19.2 | | | $ | 19.2 | | | $ | 74.5 | | | $ | 18.0 | | | $ | 18.2 | | | | | | | |
Medicare supplement | 7.8 | | | 8.9 | | | 8.7 | | | 11.5 | | | 36.9 | | | 9.7 | | | 10.3 | | | | | | | |
Long-term care | 6.2 | | | 5.7 | | | 8.9 | | | 11.1 | | | 31.9 | | | 10.6 | | | 10.7 | | | | | | | |
Total Consumer Division health NAP | 31.4 | | | 33.3 | | | 36.8 | | | 41.8 | | | 143.3 | | | 38.3 | | | 39.2 | | | | | | | |
Life products: | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | 4.6 | | | 6.3 | | | 4.4 | | | 4.5 | | | 19.8 | | | 4.4 | | | 5.0 | | | | | | | |
Traditional life | 49.7 | | | 46.0 | | | 41.9 | | | 35.5 | | | 173.1 | | | 48.8 | | | 43.2 | | | | | | | |
Total Consumer Division life NAP | 54.3 | | | 52.3 | | | 46.3 | | | 40.0 | | | 192.9 | | | 53.2 | | | 48.2 | | | | | | | |
Total Consumer Division health and life NAP | $ | 85.7 | | | $ | 85.6 | | | $ | 83.1 | | | $ | 81.8 | | | $ | 336.2 | | | $ | 91.5 | | | $ | 87.4 | | | | | | | |
Worksite Division | | | | | | | | | | | | | | | | | | | |
Health products: | | | | | | | | | | | | | | | | | | | |
Supplemental health | $ | 8.1 | | | $ | 9.8 | | | $ | 11.5 | | | $ | 10.4 | | | $ | 39.8 | | | $ | 9.5 | | | $ | 11.4 | | | | | | | |
Life products: | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | 2.8 | | | 3.3 | | | 3.7 | | | 3.9 | | | 13.7 | | | 3.5 | | | 4.1 | | | | | | | |
Total Worksite Division health and life NAP | $ | 10.9 | | | $ | 13.1 | | | $ | 15.2 | | | $ | 14.3 | | | $ | 53.5 | | | $ | 13.0 | | | $ | 15.5 | | | | | | | |
Total NAP (both divisions) | | | | | | | | | | | | | | | | | | | |
Health products: | | | | | | | | | | | | | | | | | | | |
Supplemental health | $ | 25.5 | | | $ | 28.5 | | | $ | 30.7 | | | $ | 29.6 | | | $ | 114.3 | | | $ | 27.5 | | | $ | 29.6 | | | | | | | |
Medicare supplement | 7.8 | | | 8.9 | | | 8.7 | | | 11.5 | | | 36.9 | | | 9.7 | | | 10.3 | | | | | | | |
Long-term care | 6.2 | | | 5.7 | | | 8.9 | | | 11.1 | | | 31.9 | | | 10.6 | | | 10.7 | | | | | | | |
Total health NAP | 39.5 | | | 43.1 | | | 48.3 | | | 52.2 | | | 183.1 | | | 47.8 | | | 50.6 | | | | | | | |
Life products: | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | 7.4 | | | 9.6 | | | 8.1 | | | 8.4 | | | 33.5 | | | 7.9 | | | 9.1 | | | | | | | |
Traditional life | 49.7 | | | 46.0 | | | 41.9 | | | 35.5 | | | 173.1 | | | 48.8 | | | 43.2 | | | | | | | |
Total life NAP | 57.1 | | | 55.6 | | | 50.0 | | | 43.9 | | | 206.6 | | | 56.7 | | | 52.3 | | | | | | | |
Total NAP | $ | 96.6 | | | $ | 98.7 | | | $ | 98.3 | | | $ | 96.1 | | | $ | 389.7 | | | $ | 104.5 | | | $ | 102.9 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Computation of Weighted Average Shares Outstanding
(Shares in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 (a) | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Basic | | | | | | | | | | | | | | | | | | | |
Shares outstanding, beginning of period | 114,343.1 | | | 114,905.2 | | | 113,673.9 | | | 112,163.2 | | | 114,343.1 | | | 109,357.5 | | | 108,568.6 | | | | | | | |
Weighted average share activity during the period: | | | | | | | | | | | | | | | | | | | |
Shares repurchased | (255.7) | | | (675.8) | | | (1,006.4) | | | (630.0) | | | (2,201.3) | | | (618.6) | | | (893.0) | | | | | | | |
Amounts related to employee benefit plans | 671.8 | | | 45.9 | | | 23.5 | | | 61.2 | | | 1,571.6 | | | 344.5 | | | 57.0 | | | | | | | |
Shares withheld for the payment of the exercise price and taxes related to employee benefit plans | (214.3) | | | (1.8) | | | (1.9) | | | (3.8) | | | (438.9) | | | (119.5) | | | (1.9) | | | | | | | |
Weighted average basic shares outstanding during the period | 114,544.9 | | | 114,273.5 | | | 112,689.1 | | | 111,590.6 | | | 113,274.5 | | | 108,963.9 | | | 107,730.7 | | | | | | | |
Basic shares outstanding, end of period | 114,905.2 | | | 113,673.9 | | | 112,163.2 | | | 109,357.5 | | | 109,357.5 | | | 108,568.6 | | | 106,513.6 | | | | | | | |
Diluted | | | | | | | | | | | | | | | | | | | |
Weighted average basic shares outstanding | 114,544.9 | | | 114,273.5 | | | 112,689.1 | | | 111,590.6 | | | 113,274.5 | | | 108,963.9 | | | 107,730.7 | | | | | | | |
Common stock equivalent shares related to: | | | | | | | | | | | | | | | | | | | |
Employee benefit plans | — | | | 1,376.1 | | | 1,772.8 | | | 2,066.6 | | | 1,849.5 | | | 1,881.0 | | | 1,527.5 | | | | | | | |
Weighted average diluted shares outstanding during the period | 114,544.9 | | | 115,649.6 | | | 114,461.9 | | | 113,657.2 | | | 115,124.0 | | | 110,844.9 | | | 109,258.2 | | | | | | | |
Diluted shares outstanding, end of period | 116,176.0 | | | 115,303.3 | | | 113,974.7 | | | 111,750.3 | | | 111,750.3 | | | 110,036.5 | | | 108,140.0 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
___________
(a) Equivalent common shares of 2,182.5 were not included in the weighted average shares outstanding due to the net loss recognized in 1Q23.
CNO FINANCIAL GROUP, INC.
Annuities - Account Value Rollforwards
(Dollars in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Fixed indexed annuities | | | | | | | | | | | | | | | | | | | |
Balance, beginning of period excluding contracts 100% ceded | $ | 9,490.4 | | | $ | 9,584.3 | | | $ | 9,707.7 | | | $ | 9,819.2 | | | $ | 9,490.4 | | | $ | 9,999.2 | | | $ | 10,112.7 | | | | | | | |
Issuances (funds collected from new business) | 323.3 | | | 351.6 | | | 321.7 | | | 377.1 | | | 1,373.7 | | | 345.4 | | | 388.5 | | | | | | | |
Premiums received (premiums collected from inforce business) | 0.4 | | | (0.2) | | | 0.1 | | | (0.2) | | | 0.1 | | | 0.5 | | | 0.7 | | | | | | | |
Policy charges | (4.0) | | | (5.2) | | | (5.2) | | | (5.3) | | | (19.7) | | | (6.5) | | | (7.9) | | | | | | | |
Surrenders and withdrawals | (178.2) | | | (182.6) | | | (177.6) | | | (199.9) | | | (738.3) | | | (232.2) | | | (235.2) | | | | | | | |
Benefit payments | (59.2) | | | (63.1) | | | (62.7) | | | (58.9) | | | (243.9) | | | (74.4) | | | (77.6) | | | | | | | |
Interest credited | 6.1 | | | 17.2 | | | 29.4 | | | 59.9 | | | 112.6 | | | 68.9 | | | 84.0 | | | | | | | |
Other | 5.5 | | | 5.7 | | | 5.8 | | | 7.3 | | | 24.3 | | | 11.8 | | | 13.9 | | | | | | | |
Balance, end of period excluding contracts 100% ceded | $ | 9,584.3 | | | $ | 9,707.7 | | | $ | 9,819.2 | | | $ | 9,999.2 | | | $ | 9,999.2 | | | $ | 10,112.7 | | | $ | 10,279.1 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Fixed interest annuities | | | | | | | | | | | | | | | | | | | |
Balance, beginning of period excluding contracts 100% ceded | $ | 1,663.1 | | | $ | 1,649.3 | | | $ | 1,636.6 | | | $ | 1,632.5 | | | $ | 1,663.1 | | | $ | 1,636.4 | | | $ | 1,610.6 | | | | | | | |
Issuances (funds collected from new business) | 45.3 | | | 45.8 | | | 48.4 | | | 57.5 | | | 197.0 | | | 45.1 | | | 48.5 | | | | | | | |
Premiums received (premiums collected from inforce business) | 0.7 | | | 0.9 | | | 0.5 | | | 0.6 | | | 2.7 | | | 1.0 | | | 0.5 | | | | | | | |
Policy charges | (0.2) | | | (0.2) | | | (0.3) | | | (0.3) | | | (1.0) | | | (0.3) | | | (0.3) | | | | | | | |
Surrenders and withdrawals | (43.3) | | | (42.1) | | | (39.3) | | | (39.9) | | | (164.6) | | | (52.8) | | | (42.4) | | | | | | | |
Benefit payments | (27.7) | | | (28.2) | | | (24.9) | | | (26.1) | | | (106.9) | | | (30.2) | | | (25.8) | | | | | | | |
Interest credited | 11.3 | | | 11.2 | | | 11.7 | | | 11.9 | | | 46.1 | | | 11.4 | | | 11.6 | | | | | | | |
Other | 0.1 | | | (0.1) | | | (0.2) | | | 0.2 | | | — | | | — | | | (0.1) | | | | | | | |
Balance, end of period excluding contracts 100% ceded | $ | 1,649.3 | | | $ | 1,636.6 | | | $ | 1,632.5 | | | $ | 1,636.4 | | | $ | 1,636.4 | | | $ | 1,610.6 | | | $ | 1,602.6 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Total annuities | | | | | | | | | | | | | | | | | | | |
Balance, beginning of period excluding contracts 100% ceded | $ | 11,153.5 | | | $ | 11,233.6 | | | $ | 11,344.3 | | | $ | 11,451.7 | | | $ | 11,153.5 | | | $ | 11,635.6 | | | $ | 11,723.3 | | | | | | | |
Issuances (funds collected from new business) | 368.6 | | | 397.4 | | | 370.1 | | | 434.6 | | | 1,570.7 | | | 390.5 | | | 437.0 | | | | | | | |
Premiums received (premiums collected from inforce business) | 1.1 | | | 0.7 | | | 0.6 | | | 0.4 | | | 2.8 | | | 1.5 | | | 1.2 | | | | | | | |
Policy charges | (4.2) | | | (5.4) | | | (5.5) | | | (5.6) | | | (20.7) | | | (6.8) | | | (8.2) | | | | | | | |
Surrenders and withdrawals | (221.5) | | | (224.7) | | | (216.9) | | | (239.8) | | | (902.9) | | | (285.0) | | | (277.6) | | | | | | | |
Benefit payments | (86.9) | | | (91.3) | | | (87.6) | | | (85.0) | | | (350.8) | | | (104.6) | | | (103.4) | | | | | | | |
Interest credited | 17.4 | | | 28.4 | | | 41.1 | | | 71.8 | | | 158.7 | | | 80.3 | | | 95.6 | | | | | | | |
Other | 5.6 | | | 5.6 | | | 5.6 | | | 7.5 | | | 24.3 | | | 11.8 | | | 13.8 | | | | | | | |
Balance, end of period excluding contracts 100% ceded | $ | 11,233.6 | | | $ | 11,344.3 | | | $ | 11,451.7 | | | $ | 11,635.6 | | | $ | 11,635.6 | | | $ | 11,723.3 | | | $ | 11,881.7 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Consolidated Statutory Information of U.S. Based Insurance Subsidiaries (13)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 (a) | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Net gain from operations before interest expense and federal income taxes | $ | 58.3 | | | $ | 55.6 | | | $ | 54.0 | | | $ | 67.4 | | | $ | 235.3 | | | $ | 40.3 | | | $ | 63.3 | | | | | | | |
Interest expense on surplus debentures held by parent company | 15.9 | | | 16.6 | | | 31.6 | | | 17.9 | | | 82.0 | | | 17.6 | | | 17.5 | | | | | | | |
Net gain from operations before federal income taxes | 42.4 | | | 39.0 | | | 22.4 | | | 49.5 | | | 153.3 | | | 22.7 | | | 45.8 | | | | | | | |
Federal income tax expense (benefit) | 3.3 | | | 1.9 | | | (15.0) | | | 31.8 | | | 22.0 | | | 26.7 | | | 17.7 | | | | | | | |
Net gain (loss) from operations before net realized capital gains (losses) | 39.1 | | | 37.1 | | | 37.4 | | | 17.7 | | | 131.3 | | | (4.0) | | | 28.1 | | | | | | | |
Net realized capital gains (losses) | (1.3) | | | (20.6) | | | (6.2) | | | 1.8 | | | (26.3) | | | (4.2) | | | 7.4 | | | | | | | |
Net income (loss) | $ | 37.8 | | | $ | 16.5 | | | $ | 31.2 | | | $ | 19.5 | | | $ | 105.0 | | | $ | (8.2) | | | $ | 35.5 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Capital and surplus | $ | 1,831.3 | | | $ | 1,857.0 | | | $ | 1,932.6 | | | $ | 1,558.9 | | | $ | 1,558.9 | | | $ | 1,487.3 | | | $ | 1,489.5 | | | | | | | |
Asset valuation reserve (AVR) | 317.8 | | | 316.5 | | | 333.9 | | | 352.5 | | | 352.5 | | | 351.8 | | | 369.8 | | | | | | | |
Capital, surplus and AVR | 2,149.1 | | | 2,173.5 | | | 2,266.5 | | | 1,911.4 | | | 1,911.4 | | | 1,839.1 | | | 1,859.3 | | | | | | | |
Interest maintenance reserve (IMR) | 385.6 | | | 381.7 | | | 372.1 | | | 368.1 | | | 368.1 | | | 362.1 | | | 344.0 | | | | | | | |
Total statutory capital, surplus, AVR & IMR | $ | 2,534.7 | | | $ | 2,555.2 | | | $ | 2,638.6 | | | $ | 2,279.5 | | | $ | 2,279.5 | | | $ | 2,201.2 | | | $ | 2,203.3 | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Risk-based capital ratio | 380 | % | | 386 | % | | 392 | % | | 402 | % | | 402 | % | | 391 | % | | 394 | % | | | | | | |
| | | | | | | | | | | | | | | | | | | |
___________
(a) Such amounts are preliminary as the statutory basis financial statements of our U.S. based insurance subsidiaries for 2Q24 will be filed with the respective insurance regulators on or about August 14, 2024.
CNO FINANCIAL GROUP, INC.
Investment Income Not Allocated to Product Lines (9)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| | 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Net investment income | | $ | 343.0 | | | $ | 399.7 | | | $ | 291.8 | | | $ | 465.2 | | | $ | 1,499.7 | | | $ | 469.2 | | | $ | 409.1 | | | | | | | |
Allocated to product lines: | | | | | | | | | | | | | | | | | | | | |
Annuity | | (125.4) | | | (127.7) | | | (131.0) | | | (132.2) | | | (516.3) | | | (134.5) | | | (140.5) | | | | | | | |
Health | | (74.0) | | | (74.3) | | | (74.2) | | | (74.2) | | | (296.7) | | | (74.3) | | | (75.1) | | | | | | | |
Life | | (36.3) | | | (36.1) | | | (36.3) | | | (36.1) | | | (144.8) | | | (36.5) | | | (36.7) | | | | | | | |
Equity returns credited to policyholder account balances | | (18.6) | | | (62.3) | | | 54.6 | | | (105.2) | | | (131.5) | | | (139.7) | | | (38.9) | | | | | | | |
Amounts allocated to product lines and credited to policyholder account balances | | (254.3) | | | (300.4) | | | (186.9) | | | (347.7) | | | (1,089.3) | | | (385.0) | | | (291.2) | | | | | | | |
Impact of annual option forfeitures related to fixed indexed annuity surrenders | | — | | | 1.4 | | | 2.5 | | | 3.2 | | | 7.1 | | | 6.2 | | | 6.0 | | | | | | | |
Amount related to variable interest entities and other non-operating items | | (20.9) | | | (19.0) | | | (18.7) | | | (16.2) | | | (74.8) | | | (12.6) | | | (9.6) | | | | | | | |
Interest expense on debt | | (15.7) | | | (15.6) | | | (15.7) | | | (15.7) | | | (62.7) | | | (15.7) | | | (21.8) | | | | | | | |
Interest expense on financing arrangements | | — | | | — | | | (1.1) | | | (1.3) | | | (2.4) | | | (1.2) | | | (1.2) | | | | | | | |
Interest expense on investment borrowings from the Federal Home Loan Bank ("FHLB") program | | (21.7) | | | (24.2) | | | (28.3) | | | (30.5) | | | (104.7) | | | (31.4) | | | (31.4) | | | | | | | |
Expenses related to the funding agreement-backed notes ("FABN") program (a) | | (7.6) | | | (7.6) | | | (7.6) | | | (7.6) | | | (30.4) | | | (7.6) | | | (10.9) | | | | | | | |
Less amounts credited to deferred compensation plans (offsetting investment income) | | (7.3) | | | (6.3) | | | 2.4 | | | (11.1) | | | (22.3) | | | (9.6) | | | (4.2) | | | | | | | |
Total adjustments | | (73.2) | | | (71.3) | | | (66.5) | | | (79.2) | | | (290.2) | | | (71.9) | | | (73.1) | | | | | | | |
Investment income not allocated to product lines | | $ | 15.5 | | | $ | 28.0 | | | $ | 38.4 | | | $ | 38.3 | | | $ | 120.2 | | | $ | 12.3 | | | $ | 44.8 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
___________
(a) Comprised of interest credited and amortization of deferred acquisition costs.
CNO FINANCIAL GROUP, INC.
Investment Income Not Allocated to Product Lines (9)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| | 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Investment income not allocated: | | | | | | | | | | | | | | | | | | | | |
Excluding variable components: | | | | | | | | | | | | | | | | | | | | |
From general account assets | | $ | 24.9 | | | $ | 26.4 | | | $ | 27.2 | | | $ | 29.8 | | | $ | 108.3 | | | $ | 27.1 | | | $ | 25.0 | | | | | | | |
Other investment income | | 1.9 | | | 2.0 | | | 2.4 | | | 3.0 | | | 9.3 | | | 3.1 | | | 6.8 | | | | | | | |
Spread income: | | | | | | | | | | | | | | | | | | | | |
FHLB program: | | | | | | | | | | | | | | | | | | | | |
Investment income on matched assets | | 31.8 | | | 34.7 | | | 39.4 | | | 41.5 | | | 147.4 | | | 41.7 | | | 42.4 | | | | | | | |
Interest expense | | (21.7) | | | (24.2) | | | (28.3) | | | (30.5) | | | (104.7) | | | (31.4) | | | (31.4) | | | | | | | |
Net spread income on FHLB program | | 10.1 | | | 10.5 | | | 11.1 | | | 11.0 | | | 42.7 | | | 10.3 | | | 11.0 | | | | | | | |
FABN program: | | | | | | | | | | | | | | | | | | | | |
Investment income on matched assets | | 13.8 | | | 14.6 | | | 15.8 | | | 14.8 | | | 59.0 | | | 14.9 | | | 19.6 | | | | | | | |
Expenses (b) | | (7.6) | | | (7.6) | | | (7.6) | | | (7.6) | | | (30.4) | | | (7.6) | | | (10.9) | | | | | | | |
Net spread income on FABN program | | 6.2 | | | 7.0 | | | 8.2 | | | 7.2 | | | 28.6 | | | 7.3 | | | 8.7 | | | | | | | |
Interest expense on corporate debt | | (15.7) | | | (15.6) | | | (15.7) | | | (15.7) | | | (62.7) | | | (15.7) | | | (21.8) | | | | | | | |
Interest expense on financing arrangements | | — | | | — | | | (1.1) | | | (1.3) | | | (2.4) | | | (1.2) | | | (1.2) | | | | | | | |
Total excluding variable components | | 27.4 | | | 30.3 | | | 32.1 | | | 34.0 | | | 123.8 | | | 30.9 | | | 28.5 | | | | | | | |
Variable components: | | | | | | | | | | | | | | | | | | | | |
Net income from Corporate Owned Life Insurance ("COLI") supporting agent deferred compensation plan: | | | | | | | | | | | | | | | | | | | | |
Change in value of COLI investments | | 2.2 | | | 2.4 | | | 2.6 | | | 5.8 | | | 13.0 | | | 3.6 | | | 2.9 | | | | | | | |
Increase in liability for agent deferred compensation plan | | (1.6) | | | (1.6) | | | (1.7) | | | (1.6) | | | (6.5) | | | (1.6) | | | (1.6) | | | | | | | |
Net COLI income (loss) | | 0.6 | | | 0.8 | | | 0.9 | | | 4.2 | | | 6.5 | | | 2.0 | | | 1.3 | | | | | | | |
Other variable components: | | | | | | | | | | | | | | | | | | | | |
Alternative investment income (loss): | | | | | | | | | | | | | | | | | | | | |
Total | | (9.4) | | | 0.2 | | | 6.5 | | | 0.9 | | | (1.8) | | | (24.3) | | | 11.9 | | | | | | | |
Allocated to product lines | | (7.8) | | | (7.8) | | | (7.5) | | | (7.4) | | | (30.5) | | | (7.1) | | | (6.4) | | | | | | | |
Allocated to FABN program | | — | | | — | | | — | | | — | | | — | | | — | | | (0.4) | | | | | | | |
Excess alternative investment income (loss) | | (17.2) | | | (7.6) | | | (1.0) | | | (6.5) | | | (32.3) | | | (31.4) | | | 5.1 | | | | | | | |
Trading account | | 2.6 | | | 1.3 | | | 1.3 | | | 1.3 | | | 6.5 | | | 2.1 | | | 1.0 | | | | | | | |
Hedge variance related to fixed indexed products | | — | | | (1.0) | | | (0.3) | | | (1.2) | | | (2.5) | | | 0.5 | | | — | | | | | | | |
Impact of annual option forfeitures related to fixed indexed annuity surrenders | | — | | | 1.4 | | | 2.5 | | | 3.2 | | | 7.1 | | | 6.2 | | | 6.0 | | | | | | | |
Other (a) | | 2.1 | | | 2.8 | | | 2.9 | | | 3.3 | | | 11.1 | | | 2.0 | | | 2.9 | | | | | | | |
Total variable components | | (11.9) | | | (2.3) | | | 6.3 | | | 4.3 | | | (3.6) | | | (18.6) | | | 16.3 | | | | | | | |
Total investment income not allocated to product lines | | $ | 15.5 | | | $ | 28.0 | | | $ | 38.4 | | | $ | 38.3 | | | $ | 120.2 | | | $ | 12.3 | | | $ | 44.8 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
___________
(a) Includes impacts of changes in projected cash flows, prepayment and call income and other investment income.
(b) Comprised of interest credited and amortization of deferred acquisition costs.
CNO FINANCIAL GROUP, INC.
Investment Income Allocated to Product Lines (5)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| | 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
Average net insurance liabilities (11) | | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | $ | 9,183.8 | | | $ | 9,276.0 | | | $ | 9,381.0 | | | $ | 9,508.7 | | | $ | 9,337.3 | | | $ | 9,636.3 | | | $ | 9,758.1 | | | | | | | |
Fixed interest annuities | | 1,630.9 | | | 1,613.1 | | | 1,603.0 | | | 1,600.9 | | | 1,612.0 | | | 1,588.0 | | | 1,569.4 | | | | | | | |
Other annuities | | 469.5 | | | 462.5 | | | 455.6 | | | 447.5 | | | 458.8 | | | 439.9 | | | 426.4 | | | | | | | |
Total annuity average net insurance liabilities (11) | | 11,284.2 | | | 11,351.6 | | | 11,439.6 | | | 11,557.1 | | | 11,408.1 | | | 11,664.2 | | | 11,753.9 | | | | | | | |
Health: | | | | | | | | | | | | | | | | | | | | |
Supplemental health | | 3,331.0 | | | 3,350.6 | | | 3,365.8 | | | 3,356.9 | | | 3,351.1 | | | 3,346.3 | | | 3,351.1 | | | | | | | |
Medicare supplement | | 124.2 | | | 118.7 | | | 107.1 | | | 106.7 | | | 114.2 | | | 114.8 | | | 111.6 | | | | | | | |
Long-term care | | 2,659.8 | | | 2,670.5 | | | 2,681.9 | | | 2,692.5 | | | 2,676.1 | | | 2,698.7 | | | 2,696.1 | | | | | | | |
Total health average net insurance liabilities (11) | | 6,115.0 | | | 6,139.8 | | | 6,154.8 | | | 6,156.1 | | | 6,141.4 | | | 6,159.8 | | | 6,158.8 | | | | | | | |
Life: | | | | | | | | | | | | | | | | | | | | |
Interest sensitive | | 1,032.0 | | | 1,035.4 | | | 1,039.6 | | | 1,045.8 | | | 1,038.2 | | | 1,056.1 | | | 1,063.0 | | | | | | | |
Traditional | | 1,973.0 | | | 1,975.3 | | | 1,981.8 | | | 1,989.0 | | | 1,979.8 | | | 1,994.1 | | | 1,997.3 | | | | | | | |
Total life average net insurance liabilities (11) | | 3,005.0 | | | 3,010.7 | | | 3,021.4 | | | 3,034.8 | | | 3,018.0 | | | 3,050.2 | | | 3,060.3 | | | | | | | |
Total average net insurance liabilities (11) | | $ | 20,404.2 | | | $ | 20,502.1 | | | $ | 20,615.8 | | | $ | 20,748.0 | | | $ | 20,567.5 | | | $ | 20,874.2 | | | $ | 20,973.0 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Average yield on allocated investments | | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | 4.30 | % | | 4.36 | % | | 4.45 | % | | 4.45 | % | | 4.39 | % | | 4.50 | % | | 4.66 | % | | | | | | |
Fixed interest annuities | | 5.13 | % | | 5.18 | % | | 5.24 | % | | 5.20 | % | | 5.19 | % | | 5.19 | % | | 5.38 | % | | | | | | |
Other annuities | | 4.86 | % | | 4.84 | % | | 4.92 | % | | 4.92 | % | | 4.88 | % | | 5.00 | % | | 5.25 | % | | | | | | |
Average yield on investments allocated to annuities | | 4.45 | % | | 4.50 | % | | 4.58 | % | | 4.58 | % | | 4.53 | % | | 4.61 | % | | 4.78 | % | | | | | | |
Health: | | | | | | | | | | | | | | | | | | | | |
Supplemental health | | 4.64 | % | | 4.64 | % | | 4.63 | % | | 4.62 | % | | 4.63 | % | | 4.66 | % | | 4.70 | % | | | | | | |
Medicare supplement | | 4.13 | % | | 4.19 | % | | 4.25 | % | | 4.42 | % | | 4.24 | % | | 4.73 | % | | 4.89 | % | | | | | | |
Long-term care | | 5.13 | % | | 5.12 | % | | 5.09 | % | | 5.07 | % | | 5.10 | % | | 5.02 | % | | 5.10 | % | | | | | | |
Average yield on investments allocated to health products | | 4.84 | % | | 4.84 | % | | 4.82 | % | | 4.82 | % | | 4.83 | % | | 4.82 | % | | 4.88 | % | | | | | | |
Life: | | | | | | | | | | | | | | | | | | | | |
Interest sensitive | | 5.08 | % | | 4.91 | % | | 4.96 | % | | 4.90 | % | | 4.96 | % | | 5.00 | % | | 4.97 | % | | | | | | |
Traditional | | 4.70 | % | | 4.74 | % | | 4.72 | % | | 4.69 | % | | 4.71 | % | | 4.67 | % | | 4.71 | % | | | | | | |
Average yield on investments allocated to life products | | 4.83 | % | | 4.80 | % | | 4.81 | % | | 4.76 | % | | 4.80 | % | | 4.79 | % | | 4.80 | % | | | | | | |
Total average yield | | 4.62 | % | | 4.65 | % | | 4.69 | % | | 4.68 | % | | 4.66 | % | | 4.70 | % | | 4.81 | % | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocated investment income | | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | $ | 98.8 | | | $ | 101.2 | | | $ | 104.4 | | | $ | 105.9 | | | $ | 410.3 | | | $ | 108.4 | | | $ | 113.8 | | | | | | | |
Fixed interest annuities | | 20.9 | | | 20.9 | | | 21.0 | | | 20.8 | | | 83.6 | | | 20.6 | | | 21.1 | | | | | | | |
Other annuities | | 5.7 | | | 5.6 | | | 5.6 | | | 5.5 | | | 22.4 | | | 5.5 | | | 5.6 | | | | | | | |
Total investment income allocated to annuities | | 125.4 | | | 127.7 | | | 131.0 | | | 132.2 | | | 516.3 | | | 134.5 | | | 140.5 | | | | | | | |
Health: | | | | | | | | | | | | | | | | | | | | |
Supplemental health | | 38.6 | | | 38.9 | | | 39.0 | | | 38.8 | | | 155.3 | | | 39.0 | | | 39.4 | | | | | | | |
Medicare supplement | | 1.3 | | | 1.2 | | | 1.1 | | | 1.3 | | | 4.9 | | | 1.4 | | | 1.3 | | | | | | | |
Long-term care | | 34.1 | | | 34.2 | | | 34.1 | | | 34.1 | | | 136.5 | | | 33.9 | | | 34.4 | | | | | | | |
Total investment income allocated to health products | | 74.0 | | | 74.3 | | | 74.2 | | | 74.2 | | | 296.7 | | | 74.3 | | | 75.1 | | | | | | | |
Life: | | | | | | | | | | | | | | | | | | | | |
Interest sensitive | | 13.1 | | | 12.7 | | | 12.9 | | | 12.8 | | | 51.5 | | | 13.2 | | | 13.2 | | | | | | | |
Traditional | | 23.2 | | | 23.4 | | | 23.4 | | | 23.3 | | | 93.3 | | | 23.3 | | | 23.5 | | | | | | | |
Total investment income allocated to life products | | 36.3 | | | 36.1 | | | 36.3 | | | 36.1 | | | 144.8 | | | 36.5 | | | 36.7 | | | | | | | |
Total allocated investment income | | $ | 235.7 | | | $ | 238.1 | | | $ | 241.5 | | | $ | 242.5 | | | $ | 957.8 | | | $ | 245.3 | | | $ | 252.3 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Investment Income Not Allocated to Product Lines (9)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | | | | | |
| | 2023 | | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | | | |
General account assets investment income | | $ | 292.2 | | | $ | 308.1 | | | $ | 324.8 | | | $ | 325.1 | | | $ | 1,250.2 | | | $ | 301.9 | | | $ | 351.7 | | | | | | | |
Policyholder and other special purpose portfolio investment income (loss) | | 50.8 | | | 91.6 | | | (33.0) | | | 140.1 | | | 249.5 | | | 167.3 | | | 57.4 | | | | | | | |
Less equity returns credited to policyholders: | | | | | | | | | | | | | | | | | | | | |
Annuity | | (16.5) | | | (56.1) | | | 49.8 | | | (95.5) | | | (118.3) | | | (128.6) | | | (34.9) | | | | | | | |
Life | | (2.1) | | | (6.2) | | | 4.8 | | | (9.7) | | | (13.2) | | | (11.1) | | | (4.0) | | | | | | | |
Less amount related to variable interest entities | | (20.9) | | | (19.0) | | | (18.7) | | | (16.2) | | | (74.8) | | | (12.6) | | | (9.6) | | | | | | | |
Less amounts credited to deferred compensation plans | | (7.3) | | | (6.3) | | | 2.4 | | | (11.1) | | | (22.3) | | | (9.6) | | | (4.2) | | | | | | | |
Other special purpose portfolio investment income (loss) | | 4.0 | | | 4.0 | | | 5.3 | | | 7.6 | | | 20.9 | | | 5.4 | | | 4.7 | | | | | | | |
Adjusted net investment income | | 296.2 | | | 312.1 | | | 330.1 | | | 332.7 | | | 1,271.1 | | | 307.3 | | | 356.4 | | | | | | | |
Less amounts allocated to product lines | | | | | | | | | | | | | | | | | | | | |
Annuity | | (125.4) | | | (127.7) | | | (131.0) | | | (132.2) | | | (516.3) | | | (134.5) | | | (140.5) | | | | | | | |
Health | | (74.0) | | | (74.3) | | | (74.2) | | | (74.2) | | | (296.7) | | | (74.3) | | | (75.1) | | | | | | | |
Life | | (36.3) | | | (36.1) | | | (36.3) | | | (36.1) | | | (144.8) | | | (36.5) | | | (36.7) | | | | | | | |
Total investment income allocated to product lines | | (235.7) | | | (238.1) | | | (241.5) | | | (242.5) | | | (957.8) | | | (245.3) | | | (252.3) | | | | | | | |
Impact of annual option forfeitures related to fixed indexed annuity surrenders | | — | | | 1.4 | | | 2.5 | | | 3.2 | | | 7.1 | | | 6.2 | | | 6.0 | | | | | | | |
Less interest expense on investment borrowings from FHLB program | | (21.7) | | | (24.2) | | | (28.3) | | | (30.5) | | | (104.7) | | | (31.4) | | | (31.4) | | | | | | | |
Less expenses related to FABN program | | (7.6) | | | (7.6) | | | (7.6) | | | (7.6) | | | (30.4) | | | (7.6) | | | (10.9) | | | | | | | |
Less interest expense on debt | | (15.7) | | | (15.6) | | | (15.7) | | | (15.7) | | | (62.7) | | | (15.7) | | | (21.8) | | | | | | | |
Less interest expense on financing arrangements | | — | | | — | | | (1.1) | | | (1.3) | | | (2.4) | | | (1.2) | | | (1.2) | | | | | | | |
Investment income not allocated to product lines | | $ | 15.5 | | | $ | 28.0 | | | $ | 38.4 | | | $ | 38.3 | | | $ | 120.2 | | | $ | 12.3 | | | $ | 44.8 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
Other Investment Data
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | 1Q | | 2Q | | | | |
| | 2023 | | 2023 | | 2023 | | 2023 | | 2024 | | 2024 | | | | |
Average book value of invested assets and cash | | $ | 26,801.8 | | | $ | 26,900.3 | | | $ | 27,287.6 | | | $ | 27,648.7 | | | $ | 27,897.0 | | | $ | 28,577.4 | | | | | |
Net investment income from general account investments | | 292.2 | | | 308.1 | | | 324.8 | | | 325.1 | | | 301.9 | | | 351.7 | | | | | |
New money rate (14) | | 6.34 | % | | 6.32 | % | | 6.03 | % | | 6.92 | % | | 6.17 | % | | 6.41 | % | | | | |
Book yield (15) | | 4.56 | % | | 4.58 | % | | 4.60 | % | | 4.62 | % | | 4.64 | % | | 4.73 | % | | | | |
Earned yield (16) | | 4.22 | % | | 4.41 | % | | 4.55 | % | | 4.49 | % | | 4.06 | % | | 4.71 | % | | | | |
Alternative investment income (loss) | | (9.4) | | | 0.2 | | | 6.5 | | | 0.9 | | | (24.3) | | | 11.9 | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
4Q23 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 4Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 63.6 | | | $ | (12.9) | | (a) | $ | 50.7 | |
Health margin | | 146.4 | | | (22.3) | | (a) | 124.1 | |
Life margin | | 64.6 | | | 1.3 | | (a) | 65.9 | |
Total insurance product margin | | 274.6 | | | (33.9) | | | 240.7 | |
Allocated expenses | | (138.8) | | | — | | | (138.8) | |
Income from insurance products (5) | | 135.8 | | | (33.9) | | | 101.9 | |
Fee income | | 17.8 | | | — | | | 17.8 | |
Investment income not allocated to product lines (9) | | 38.3 | | | — | | | 38.3 | |
Expenses not allocated to product lines | | (19.8) | | | — | | | (19.8) | |
Operating earnings before taxes | | 172.1 | | | (33.9) | | | 138.2 | |
Income tax (expense) benefit on operating income | | (38.2) | | | 7.5 | | | (30.7) | |
Net operating income (10) | | $ | 133.9 | | | $ | (26.4) | | | $ | 107.5 | |
| | | | | | |
Net operating income per diluted share | | $ | 1.18 | | | $ | (0.23) | | | $ | 0.95 | |
___________
(a)Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial assumption and model review.
CNO FINANCIAL GROUP, INC.
3Q23 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 3Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | September 30, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 57.0 | | | $ | — | | | $ | 57.0 | |
Health margin | | 123.2 | | | — | | | 123.2 | |
Life margin | | 59.8 | | | — | | | 59.8 | |
Total insurance product margin | | 240.0 | | | — | | | 240.0 | |
Allocated expenses | | (153.2) | | | — | | | (153.2) | |
Income from insurance products (5) | | 86.8 | | | — | | | 86.8 | |
Fee income | | (2.9) | | | — | | | (2.9) | |
Investment income not allocated to product lines (9) | | 38.4 | | | — | | | 38.4 | |
Expenses not allocated to product lines | | 7.5 | | | (21.7) | | (a) | (14.2) | |
Operating earnings before taxes | | 129.8 | | | (21.7) | | | 108.1 | |
Income tax (expense) benefit on operating income | | (28.5) | | | 4.8 | | | (23.7) | |
Net operating income (10) | | $ | 101.3 | | | $ | (16.9) | | | $ | 84.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.88 | | | $ | (0.14) | | | $ | 0.74 | |
___________
(a)Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals.
CNO FINANCIAL GROUP, INC.
4Q22 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 4Q22 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 50.8 | | | $ | 3.2 | | (a) | $ | 54.0 | |
Health margin | | 140.4 | | | (18.3) | | (a) | 122.1 | |
Life margin | | 43.3 | | | 14.4 | | (a) | 57.7 | |
Total insurance product margin | | 234.5 | | | (0.7) | | | 233.8 | |
Allocated expenses | | (149.1) | | | — | | | (149.1) | |
Income from insurance products (5) | | 85.4 | | | (0.7) | | | 84.7 | |
Fee income | | 9.2 | | | — | | | 9.2 | |
Investment income not allocated to product lines (9) | | 25.2 | | | — | | | 25.2 | |
Expenses not allocated to product lines | | (12.8) | | | — | | | (12.8) | |
Operating earnings before taxes | | 107.0 | | | (0.7) | | | 106.3 | |
Income tax (expense) benefit on operating income | | (24.1) | | | 0.2 | | | (23.9) | |
Net operating income (10) | | $ | 82.9 | | | $ | (0.5) | | | $ | 82.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.71 | | | $ | — | | | $ | 0.71 | |
___________
(a)Comprised of $.7 million of the net favorable impact arising from our comprehensive annual actuarial assumption and model review.
CNO FINANCIAL GROUP, INC.
2Q22 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 2Q22 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | June 30, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 60.1 | | | $ | — | | | $ | 60.1 | |
Health margin | | 125.4 | | | — | | | 125.4 | |
Life margin | | 70.2 | | | — | | | 70.2 | |
Total insurance product margin | | 255.7 | | | — | | | 255.7 | |
Allocated expenses | | (152.2) | | | — | | | (152.2) | |
Income from insurance products (5) | | 103.5 | | | — | | | 103.5 | |
Fee income | | 3.2 | | | — | | | 3.2 | |
Investment income not allocated to product lines (9) | | 64.6 | | | — | | | 64.6 | |
Expenses not allocated to product lines | | 2.9 | | | (22.5) | | (a) | (19.6) | |
Operating earnings before taxes | | 174.2 | | | (22.5) | | | 151.7 | |
Income tax (expense) benefit on operating income | | (39.1) | | | 5.1 | | | (34.0) | |
Net operating income (10) | | $ | 135.1 | | | $ | (17.4) | | | $ | 117.7 | |
| | | | | | |
Net operating income per diluted share | | $ | 1.15 | | | $ | (0.15) | | | $ | 1.00 | |
___________
(a)Comprised of an experience refund of $22.5 million related to a reinsurance agreement.
Notes
(1)Excludes accumulated other comprehensive income (loss). Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(2)Shareholders' equity divided by common shares outstanding.
(3)Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period.
(4)Insurance margin is management’s measure of profitability of its annuity, health and life product lines’ performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs. Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of results of our insurance product lines. Income from insurance products, a non-GAAP measure, is a component of net operating income, which is reconciled to net income on page 5 of this Quarterly Financial Supplement.
(5)Investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average net insurance liabilities for the block in each period. See note (11) for definition of net insurance liabilities.
(6)Excludes the change in market values of the underlying options supporting the fixed indexed annuity products and corresponding amount credited to policyholder account balances. Such amounts were $16.5 million, $56.1 million, $(49.8) million, $95.5 million, $128.6 million and $34.9 million in 1Q23, 2Q23, 3Q23, 4Q23, 1Q24 and 2Q24, respectively.
(7)Excludes the change in market values of the underlying options supporting the fixed indexed life products and corresponding amount credited to policyholder account balances. Such amounts were $2.1 million, $6.2 million, $(4.8) million, $9.7 million, $11.1 million and $4.0 million in 1Q23, 2Q23, 3Q23, 4Q23, 1Q24 and 2Q24, respectively.
(8)Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of results of our insurance product lines. Income from insurance products, a non-GAAP measure, is a component of net operating income, which is reconciled to net income on page 5 of this Quarterly Financial Supplement.
(9)Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our Federal Home Loan Bank investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investments income not allocated to product lines), net of interest expense on corporate debt and financing arrangements.
(10)Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transaction, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes (“net operating income,” a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals.
(11)Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
(12)Margin/average net insurance liabilities for quarterly periods is calculated by annualizing the quarters' margin divided by the average net insurance liabilities.
(13)Based on statutory accounting practices prescribed or permitted by regulatory authorities for CNO Financial's U.S. based insurance subsidiaries after appropriate elimination of intercompany accounts among such subsidiaries. Such accounting practices differ from GAAP.
(14)The new money rate is for the investments purchased during the period to support our insurance products and capital. It excludes the new money rate on investments purchased with investment borrowings under our Federal Home Loan Bank and FABN programs and investments purchased by the variable interest entities.
Notes (continued)
(15)Book yield on fixed maturity investments, excluding investments held in the: (i) Federal Home Loan Bank and FABN programs; and (ii) the investments held by the variable interest entities.
(16)Earned yield is the investment income earned during the period divided by the average book value of the investment portfolio, excluding: (i) investments held in the Federal Home Loan Bank and FABN programs; and (ii) the investments held by the variable interest entities.
1 Unless otherwise specified, comparisons in this presentation are between 2Q23 and 2Q24. Second Quarter 2024 Financial and operating results for the period ended June 30, 2024 July 29, 2024 Exhibit 99.3
2 Certain statements made in this presentation should be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These include statements about future results of operations and capital plans. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ, including those included in our press release issued on July 29, 2024, our Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. We assume no obligation to update this presentation, which speaks as of today’s date. Forward-Looking Statements This presentation contains financial measures that differ from the comparable measures under Generally Accepted Accounting Principles (GAAP). Reconciliations between those non-GAAP measures and the comparable GAAP measures are included in the Appendix, or on the page such measure is presented. While management believes the measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered substitutes for the most directly comparable GAAP measures. Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the “Investors – Financials – SEC Filings” section of CNO’s website, CNOinc.com. Non-GAAP Measures IMPORTANT LEGAL INFORMATION
3 OUR PURPOSE We secure the future of middle-income America. OUR MISSION We secure the future of middle-income America by providing insurance and financial services that help protect their health, income and retirement needs, while building enduring value for all our stakeholders.
4 1 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. Operational Highlights 8th consecutive quarter of strong sales momentum – Total new annualized premiums (NAP) up 4% – Annuity collected premiums up 9% Total producing agent count (PAC) up 5%; 6th consecutive quarter of growth Policyholder and client assets up 9% Recent new product introductions and successful recruiting strategies driving growth momentum Financial Highlights QUARTER IN REVIEW Strength in production, earnings and capital Operating EPS1 of $1.05, up 94% – Strong underwriting and investment income results New money rate above 6% for the 6th consecutive quarter, average yield on allocated investments up 16 basis points Capital and liquidity remain above target levels; strong free cash flow generation – Issued $700 million of senior unsecured notes Returned $77 million to shareholders Book value per diluted share excluding AOCI1 was $36.00, up 11%
5 1 Measured as 100% of new life and health annualized premiums, except for single premium whole life deposits, which are measured at 10% of annualized premium. 2 Represents fee revenue from the sales of third-party insurance products; fees generated by our broker/dealer and registered investment advisor; fee revenue earned by Optavise. 3 Client assets include cash and securities in brokerage, broker/dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts. 4 Excluding accumulated other comprehensive income (loss) (a non-GAAP measure). See the Appendix for a reconciliation to the corresponding GAAP measure. GROWTH SCORECARD Growth in all scorecard metrics (dollars in millions) 2Q 3Q 4Q FY 1Q 2Q vs 2Q23 New Annualized Premiums1 $98.7 $98.3 $96.1 $389.7 $104.5 $102.9 4.3% Consumer 85.6 83.1 81.8 336.2 91.5 87.4 2.1% Worksite 13.1 15.2 14.3 53.5 13.0 15.5 18.3% Annuity Collected Premiums $401.8 $372.2 $438.3 $1,583.2 $393.3 $439.1 9.3% Fee Revenue2 $29.4 $27.9 $69.0 $177.6 $50.5 $32.0 8.8% Policyholder and Client Assets $14,272 $14,357 $14,804 -- $15,169 $15,509 8.7% Annuity Account Values 11,344 11,452 11,636 -- 11,723 11,882 4.7% Client Assets in BD and Advisory 3 2,928 2,905 3,168 -- 3,446 3,627 23.9% Producing Agent Counts 4,589 4,588 4,573 -- 4,690 4,811 4.8% Consumer 4,279 4,267 4,224 -- 4,322 4,422 3.3% Worksite 310 321 349 -- 368 389 25.5% Average Book Value of Investments & Cash $26,900 $27,288 $27,649 -- $27,897 $28,577 6.2% Average Yield on Allocated Investments 4.65% 4.69% 4.68% 4.66% 4.70% 4.81% 16 bps New Money Rate 6.32% 6.03% 6.92% -- 6.17% 6.41% 9 bps Book Value per Diluted Share x AOCI 4 $32.34 $33.75 $33.94 -- $34.97 $36.00 11.3% 2-year CAGR 13.9% 14.6% 12.4% -- 11.2% 8.6% -- IN V E S T M E N T S & C A P IT A L Change2023 P R O D U C T IO N D IS T R IB U T IO N 2024
6 CONSUMER DIVISION UPDATE Successful execution delivering consistent and sustainable sales growth; 7th consecutive quarter of sales growth PAC up 3%, 6th consecutive quarter of growth – Recruiting up 1%, 8th consecutive quarter of growth Agent productivity and retention remain strong Continued disciplined and opportunistic approach to D2C advertising spend NAP generated from web/digital channels up 4%, now represents ~28% of total D2C Life and Health NAP up 2%, field agent NAP up 8% Health NAP up 18%; Medicare Supplement NAP up 16%; LTC NAP up 88% Annuity collected premiums up 9%; account value up 5% Medicare Advantage policies sold up 78% Client assets in brokerage and advisory up 24% to a record $3.6B – New accounts up 9% Operational Highlights Distribution Highlights
7 WORKSITE DIVISION UPDATE Insurance sales momentum continues; 9th consecutive quarter of NAP growth Life and Health NAP up 18% – At least +15% growth in 8 of the last 9 quarters New products driving growth – Accident product up 27% – Critical Illness product up 16% Fee sales1 up 24% New employer groups up 8% PAC up 25%, first-year PAC up 33% Agent productivity up 7% Continued success with geographic expansion, contributing 32% of NAP growth in the quarter Operational Highlights Distribution Highlights 1 Fee sales represents the annualized value of fee-based services contracts executed in the quarter.
81 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. $114.6$62.3Net operating income1 109.3115.6 Weighted average shares outstanding (in millions) $0.54 $1.05 Net operating earnings per share1 Second Quarter 2024 (dollars in millions, except where noted) Earnings Results FINANCIAL HIGHLIGHTS Operating EPS growth driven by strong results across the board 2Q23 2Q24 Operating EPS1 of $1.05, up 94% — Strong insurance product margins across all major product lines — NII allocated to products, benefiting from growing asset base and 16 bps improvement in yield — NII not allocated to products benefitting from improved alternative investment returns Capital position supported by strong free cash flow generation and recent debt offering $60 million of share repurchases Operating ROE1 excluding significant items, as adjusted, of 10.0%. As reported Operating ROE1 of 11.2%
9 (dollars in millions) Insurance Product Margin Excluding Significant Items1 1 Excludes $12.9 million favorable annuity unlocking, $22.3 million favorable health unlocking and $1.3 million unfavorable life unlocking in 4Q23. See the Appendix for a reconciliation to the corresponding GAAP measure. Annuity margin Fixed Indexed Annuities – improved spread benefiting from portfolio optimization trades in the quarter and growth in the block Other Annuities – favorable reserve releases due to higher mortality on closed block policies Health margin Supplemental Health – growth in the block Medicare Supplement – favorable claims experience LTC – favorable claims and growth in the block Life margin Traditional Life – growth in the block and lower nondeferrable advertising expense Highlights INSURANCE PRODUCT MARGIN Strong underwriting margin across all major product lines 2Q23 3Q23 4Q23 1Q24 2Q24 Annuity $57.1 $57.0 $50.7 $52.0 $76.1 Fixed indexed annuities $47.6 $47.2 $41.5 $43.4 $49.9 Fixed interest annuities $8.7 $8.4 $7.7 $7.6 $8.7 Other annuities $0.8 $1.4 $1.5 $1.0 $17.5 Health $108.2 $123.2 $124.1 $123.0 $135.9 Supplemental health $59.9 $62.8 $66.5 $65.4 $65.1 Medicare supplement $32.3 $37.2 $31.9 $26.5 $35.5 Long-term care $16.0 $23.2 $25.7 $31.1 $35.3 Life $57.9 $59.8 $65.9 $54.6 $63.1 Interest sensitive life $24.1 $22.9 $25.0 $22.5 $23.9 Traditional life $33.8 $36.9 $40.9 $32.1 $39.2 Total Margin $223.2 $240.0 $240.7 $229.6 $275.1
10 1 Reflects sum of allocated and non-allocated investment income. Refer to pages 15-18 of the financial supplement for more information on the components of net investment income. 2 Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities. Average yield on allocated investments of 4.81% vs. 4.65% in 2Q23 Average net insurance liabilities 2 up 2% New money rate of 6.41%, compared to 6.17% in 1Q24 and 6.32% in 2Q23 Average book value of invested assets up 6%; 8th consecutive quarter of book yield increase Earned yield of 4.71%, compared to 4.06% in 1Q24 and 4.41% in 2Q23 Investment income not allocated to product lines up $17 million Improved alternative investment income FHLB/FABN margins benefited from asset quality and $750 million FABN offering in the quarter Investment Income Allocated to Product Lines Investment Income Not Allocated to Product Lines Total Net Investment Income1 Annuity Health Life Not allocated $- $100.0 $200.0 $300.0 2Q 2023 2Q 2024 $252.3 $238.1 $28.0 $44.8 $- $100.0 $200.0 $300.0 2Q 2023 2Q 2024 $- $100.0 $200.0 $300.0 2Q 2023 2Q 2024 $297.1 $266.1 INVESTMENT RESULTS Strong net investment income (dollars in millions)
11 1 Fair Value as of 06/30/2024 PORTFOLIO COMPOSITION High-quality portfolio delivering strong net investment income Highlights General Approach IG Corporates, 42.5% Non- Agency RMBS, 6.2% Mortgage Loans, 7.4% HY Corporates, 2.0% CMBS, 8.7% Municipals, 10.3% ABS, 5.7% Govts/Agency, 3.8% CLO, 4.4% Equities, 0.5% Other Invested Assets, 3.2% Alternatives, 2.5% Policy Loans, 0.5% Cash, 2.5% $28 Billion of Invested Assets1 High degree of liquidity: over 60% of portfolio in corporate and government bonds Strong credit risk profile — Capital efficient: 97% rated NAIC 1 or 2 — Portfolio average rating A — CRE portfolio performing as expected Positioned for stable performance across credit cycles Focus on quality - margin against adverse development Low impairments through multiple cycles Embedded asset liability management Opportunistic investments protect/grow book yield and core earnings power
12 Debt to Capital2 Consolidated Risk Based Capital (RBC) Ratio1 Holding Company Liquidity 384% 402% 391% 394% 2022 2023 1Q24 2Q24 $167 $256 $223 $429 2022 2023 1Q24 2Q24 23.4% 23.1% 22.9% 32.0% 2022 2023 1Q24 2Q24 1 The ratio of the combined capital of the insurance companies to the minimum amount of capital appropriate to support the overall business operations, as determined based on the methodology developed by the National Association of Insurance Commissioners. 2 Excluding accumulated other comprehensive income (loss) (a non-GAAP measure). See the Appendix for a reconciliation to the corresponding GAAP measure. (dollars in millions) Target consolidated RBC ratio of approximately 375% RBC variability expected in periods of market volatility Target leverage of 25% - 28% Reported result of 32.0%2 includes $500 million note maturing May 2025, expected to be repaid with proceeds from the recent $700 million debt issuance. Excluding this note, debt to capital is 25.5%2 Debt covenant ceiling of 35% $180 million in debt capacity to top of target leverage range, assuming repayment of 2025 Notes Target minimum holding company liquidity of $150 million Liquidity backstopped by $250 million undrawn revolver Issued $700 million in senior unsecured notes in the quarter, $500 million earmarked for repayment of May 2025 maturity Staggered debt maturities in 2029 and 2034 CAPITAL AND LIQUIDITY OVERVIEW Capital and liquidity remain above target levels 25.5% Debt to capital2 excluding $500 million note maturing May 2025
13 Earnings $3.30 - $3.50 operating EPS 19.0% – 19.2% expense ratio ~23% effective tax rate $200 – $250 million excess cash flow to holding company 375% consolidated RBC ratio target $150 million minimum holding company liquidity 25% – 28% target leverage Free Cash Flow / Excess Capital 2024 OUTLOOK Raising full-year guidance on earnings and cash flow Guidance excludes significant items
14 4 5 3 2 1 Exclusive focus on underserved middle-income market Significant demographic tailwinds Diverse and integrated "last mile" virtual and in-person model Sustainable growth initiatives delivering results Strong balance sheet and solid free cash flow generation WHY INVEST IN CNO
15 Questions and Answers
16 Cash Flow Profile Slide 17 Broker-Dealer/Registered Investment Advisor Slide 18 Expense Ratio Slide 19 New Money Rate Walk Slide 20 New Money Summary Slide 21 Commercial Mortgage Loans Slide 22 Commercial Mortgage-Backed Securities Slide 23 Long-Term Care Insurance Slide 24 Tax Asset Summary Slide 25 Appendix 1: Quarter in Review
17 1 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. 2 Cash flows exclude acquisitions, dividend payments, stock repurchases, and financing transactions (dollars in millions) CASH FLOW PROFILE 2Q23 2Q24 2Q23 2Q24 Net Operating Income1 62.3$ 114.6$ 281.7$ 407.3$ Holding Company Cash Flows: Net Dividends (Contributions) from/to Subsidiaries 59.0$ 56.3$ 148.6$ 259.1$ Management Fees 29.6 28.4 121.6 115.6 Surplus Debenture Interest 16.6 17.5 67.2 84.6 Earnings on Corporate Investments 3.3 4.8 13.7 17.6 Other 12.5 11.2 3.7 (7.7) Holding Company Sources of Cash 2 121.0 118.2 354.8 469.2 Holding Company Expenses and Other (15.6) (12.7) (78.7) (68.0) Intercompany Tax Receipts (Payments) 4.0 41.6 (19.3) 73.0 Tax Payments (15.3) (26.6) (29.9) (63.5) Interest Payments (28.3) (28.3) (60.8) (60.8) Excess Cash Flow to Holding Company 2 65.8 92.2 166.1 349.9 Net Proceeds from the Issuance of Notes Payable - 691.0 - 691.0 Share Repurchases (29.7) (59.7) (64.2) (219.8) Dividend Payments to Stockholders (17.5) (17.2) (66.7) (68.1) Net Change in Holding Company Cash and Investments 18.6 706.3 35.2 753.0 Cash and Investments, Beginning of Period 157.5 222.8 140.9 176.1 Cash and Investments, End of Period 176.1$ 929.1$ 176.1$ 929.1$ Amounts Invested for the Future Repayment of Notes Payable 0.0 (500.0) 0.0 (500.0) Available Cash and Investments, End of Period 176.1$ 429.1$ 176.1$ 429.1$ Trailing Twelve MonthsFor the Quarter
18 Account values up 24% YoY; Record $3.6 billion in client assets 1 Client assets include cash and securities in brokerage, broker/dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts. Prior periods have been restated to conform with current presentation. Bankers Life is the marketing brand of various affiliated companies of CNO Financial Group including, Bankers Life and Casualty Company, Bankers Life Securities, Inc., and Bankers Life Advisory Services, Inc. Non-affiliated insurance products are offered through Bankers Life General Agency, Inc. (dba BL General Insurance Agency, Inc., AK, AL, CA, NV, PA). Agents who are financial advisors are registered with Bankers Life Securities, Inc. Securities and variable annuity products and services are offered by Bankers Life Securities, Inc. Member FINRA/SIPC, (dba BL Securities, Inc., AL, GA, IA, IL, MI, NV, PA). Advisory products and services are offered by Bankers Life Advisory Services, Inc. SEC Registered Investment Adviser (dba BL Advisory Services, Inc., AL, GA, IA, MT, NV, PA). Home Office: 303 East Wacker Drive, 5th Floor, Chicago, IL 60601. 2 Registered agents are dually licensed as insurance agents and financial representatives who can buy and sell securities for clients, and/or investment advisors who can provide ongoing investment advice for clients. 3 Representative counts represent the average of the last 3 months. (dollars in millions) BROKER-DEALER/REGISTERED INVESTMENT ADVISOR 2Q 3Q 4Q 1Q 2Q Net New Client Assets in Brokerage (4.2)$ 16.7$ (1.0)$ 10.5$ 55.9$ Brokerage and Advisory1 Advisory 41.8 47.8 18.7 57.7 82.9 Total 37.6$ 64.5$ 17.7$ 68.2$ 138.8$ Client Assets in Brokerage and Brokerage 1,626.1$ 1,597.6$ 1,729.8$ 1,855.6$ 1,932.2$ Advisory1 at end of period Advisory 1,302.0 1,307.6 1,438.2 1,590.4 1,694.6 Total 2,928.1$ 2,905.2$ 3,168.0$ 3,446.0$ 3,626.8$ Registered Agent Counts 2,3 Total 695 701 708 710 718 2023 2024
19 1 Expenses allocated to products plus not allocated to products, divided by the sum of insurance policy income and net investment income allocated to products. Results exclude significant items. 2 See page 28 for a reconciliation of the significant item. EXPENSE RATIO1 (dollars in millions) 2Q 3Q 4Q 1Q 2Q Allocated & Non Allocated Expenses 170.6$ 145.7$ 158.6$ 178.4$ 172.1$ Allocated & Non Allocated Expenses - YTD 346.4 492.1 650.7 178.4 350.5 Significant Items2 -$ (21.7)$ -$ -$ -$ Significant Items - YTD2 - (21.7) (21.7) - - Allocated & Non Allocated Expenses Excluding Significant Items 170.6$ 167.4$ 158.6$ 178.4$ 172.1$ Allocated & Non Allocated Expenses Excluding Significant Items- YTD 346.4 513.8 672.4 178.4 350.5 Policy Income and Net Investment Income Allocated to Products 866.4$ 867.5$ 868.2$ 873.7$ 893.8$ Policy Income and Net Investment Income Allocated to Products - YTD 1,727.6 2,595.1 3,463.3 873.7 1,767.5 Expense Ratio excluding Significant Items 19.7% 19.3% 18.3% 20.4% 19.3% Expense Ratio excluding Significant Items - YTD 20.1% 19.8% 19.4% 20.4% 19.8% Rolling Twelve Months Ratio 19.6% 19.6% 19.4% 19.4% 19.3% 2023 2024
20 NEW MONEY RATE WALK 1QNMR Yield Curve Spread Duration Direct Investment 2Q24 NMR 6.17% 0.30% 0.09% -0.04% -0.11% 6.41%
21 2Q24 General Account New Money Purchases NEW MONEY SUMMARY (dollars in millions) IG Corp BBB 21.6% IG Corp AAA-A 17.0% Municipals 16.9% Residential Mortgage Loans 13.9% CRE Loans 8.1% RMBS 6.2% Alternatives 4.2% ABS 4.1% CLO Debt 3.0% HY Corp 2.5% CMBS 1.8% EM 0.6% $ % GAAP YTM Duration IG Corp BBB 182.0 21.6% 6.17% 7.39 IG Corp AAA-A 143.3 17.0% 5.95% 9.43 Municipals 142.5 16.9% 5.89% 11.23 Residential Mortgage Loans 116.5 13.9% 6.88% 2.96 CRE Loans 68.5 8.1% 5.90% 6.26 RMBS 52.0 6.2% 6.22% 3.20 Alternatives 35.2 4.2% 9.28% 4.04 ABS 34.2 4.1% 6.78% 5.13 CLO Debt 25.2 3.0% 6.45% 6.12 HY Corp 21.1 2.5% 9.40% 1.00 CMBS 14.9 1.8% 6.34% 3.54 EM 5.4 0.6% 6.02% 8.17 Total 840.6 100% 6.41% 6.93
22 Prop Type Avg LTV (%) Apartment 50.2 Industrial 44.0 Mixed Use 42.1 Office 58.7 Other 27.3 Retail 40.2 37.8% 19.5% 19.1% 13.0% 5.4% 5.1% <40% 40-50% 50-60% 60-70% 70-80% >80% Our CRE loan portfolio emphasizes lower risk sectors Our CRE loan portfolio is conservatively margined with cushion for adverse development We emphasize stabilized cash flowing properties DSCR Our CRE loan portfolio is not significantly exposed to 2024/2025 maturity default risk (dollars in millions) % o f T o ta l A U M LTV COMMERCIAL MORTGAGE LOANS M a tu rit ie s ($ m m ) One delinquent loan in the last 8 years Apartment $447.9 36.7% Industrial $341.0 28.0%Mixed Use $15.6 1.3% Office $121.7 10.0% Other $91.0 7.5% Retail $202.6 16.6% $20.1 $9.8 $52.8 $82.3 2024 2025 2026 2027 49.9% 19.2% 18.7% 10.7% 1.5% 0.0% >2.00x 1.70-2.00x 1.40-1.70x 1.15-1.40x 1.00-1.15x <1.00x
23 AAA, $1,794 , 72% AA+, $71 , 3% AA, $43 , 2% AA-, $99 , 4% A+, $100 , 4% A, $101 , 4% A-, $60 , 2% BBB+, $47 , 2% BBB, $91 , 4% BBB-, $12 , 0% BB, $67 , 3% Source: NAIC Loss Scenario Our CMBS investments have significant structural cushion for collateral losses Our holdings have limited loss content in severe scenarios Change in CRE Values – NAIC Scenarios BearBull Estimated Life of Portfolio CNO Principal Loss Our CMBS allocation is tilted toward lower risk property types Our CMBS allocation is highly rated - 91% AAA/AA/A categories 73% of our CMBS investments are considered ‘no-loss’ in 2024 NAIC scenario testing The composition in the 10% credit support bucket: 50% Freddie K, 30% SASB, 20% Conduit. Base Case Loss <50bps. % L o ss A b so rb in g S u b o rd in a tio n in S tr u ct u re (dollars in millions) COMMERCIAL MORTGAGE-BACKED SECURITIES 11% 17% 22% 50% <10 10-15 15-30 >30 CNO Index Multifamily Office Other Industrial Retail Hotel 6.6 8.2 9.2 13.0 18.6 22.2 26.0 32.5 10% 6% -1% -10% -19% -24% -29% -40%
24 New sales (~$50 million annually) focused on short duration products Recent growth due to launch of new LTC Fundamental product 99% of new sales for policies with 2 years or less in benefits Average benefit period of 12 months New business 25% reinsured since 2008 Reserve assumptions informed by historical experience No morbidity improvement No mortality improvement Minimal future rate increases Favorable economic profile Total LTC is just 12.6% of overall CNO insurance liabilities Downside risk significantly reduced after 2018 reinsurance transaction Average maximum benefit at issuance is $163 per day for inforce block Block highlights Less than 25% of policies have inflation benefits 2.3% of policies have lifetime benefits, the median benefit period is 1 year, and the average non-lifetime benefit period is ~1.4 years Average attained age is 74.6 years Highly differentiated inforce block; Prudently managed LONG-TERM CARE INSURANCE
25 Value of NOLs Details Effective January 1, 2024, the Company changed its method of accounting for indirect costs allocable to self-constructed real estate assets. This tax method change will result in a current year deduction of certain costs previously capitalized under the prior method. As a result, the Company recognized a loss of $985 million in the first quarter of 2024 for tax reporting purposes. In 2024, the loss will offset 100% of non- life taxable income and 35% of life taxable income. Any remaining loss after 2024 can be carried forward indefinitely but will be limited each year to 80% of non-life taxable income and 35% of life taxable income pursuant to tax regulations. In May 2024, the Internal Revenue Service ("IRS") changed the requirements as it relates to the above tax method accounting change. Previously this tax method accounting change was automatically accepted by the IRS, now the IRS requires companies to obtain approval. The Company requested approval for this method change in June 2024. Remaining non-life NOLs with expiration dates ranging from 2026 through 2035 are expected to be fully utilized and can offset 100% of non-life taxable income and 35% of life taxable income. Total estimated economic value of tax assets related to our NOLs and tax strategy of approximately $212 million @ 10% discount rate ($1.96 on a per share basis). $297 (dollars in millions) $297 million / $2.75 per diluted share value of remaining NOLs Non-Life NOLs with Expiration Dates (2026-2035) $77 2024 Non-Life Tax Loss $220 TAX ASSET SUMMARY AS OF JUNE 30, 2024
26 Appendix 2: Financial Exhibits Non-GAAP Financial Measures Slides 27 - 41
27 Insurance product margin Annuity 63.6$ (12.9)$ (1) 50.7$ Health 146.4 (22.3) (1) 124.1 Life 64.6 1.3 (1) 65.9 Total insurance product margin 274.6 (33.9) 240.7 Allocated expenses (138.8) - (138.8) Income from insurance products 135.8 (33.9) 101.9 Fee income 17.8 - 17.8 Investment income not allocated to product lines 38.3 - 38.3 Expenses not allocated to product lines (19.8) - (19.8) Operating earnings before taxes 172.1 (33.9) 138.2 Income tax (expense) benefit on operating income (38.2) 7.5 (30.7) Net operating income (2) 133.9$ (26.4)$ 107.5$ Net operating income per diluted share (2) 1.18$ 0.23$ 0.95$ Three months ended December 31, 2023 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Impacts arising from our comprehensive annual actuarial review. (2) A non-GAAP measure. See pages 30 and 32 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 4Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 4Q23 SIGNIFICANT ITEMS
28 Insurance product margin Annuity 57.0$ -$ 57.0$ Health 123.2 - 123.2 Life 59.8 - 59.8 Total insurance product margin 240.0 - 240.0 Allocated expenses (153.2) - (153.2) Income from insurance products 86.8 - 86.8 Fee income (2.9) - (2.9) Investment income not allocated to product lines 38.4 - 38.4 Expenses not allocated to product lines 7.5 (21.7) (1) (14.2) Operating earnings before taxes 129.8 (21.7) 108.1 Income tax (expense) benefit on operating income (28.5) 4.8 (23.7) Net operating income (2) 101.3$ (16.9)$ 84.4$ Net operating income per diluted share (2) 0.88$ (0.14)$ 0.74$ Three months ended September 30, 2023 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals. (2) A non-GAAP measure. See pages 30 and 32 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 3Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 3Q23 SIGNIFICANT ITEMS
29 Insurance product margin Annuity 50.8$ 3.2$ (1) 54.0$ Health 140.4 (18.3) (1) 122.1 Life 43.3 14.4 (1) 57.7 Total insurance product margin 234.5 (0.7) 233.8 Allocated expenses (149.1) - (149.1) Income from insurance products 85.4 (0.7) 84.7 Fee income 9.2 - 9.2 Investment income not allocated to product lines 25.2 - 25.2 Expenses not allocated to product lines (12.8) (12.8) Operating earnings before taxes 107.0 (0.7) 106.3 Income tax (expense) benefit on operating income (24.1) 0.2 (23.9) Net operating income (2) 82.9$ (0.5)$ 82.4$ Net operating income per diluted share (2) 0.71$ -$ 0.71$ Three months ended December 31, 2022 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Impacts arising from our comprehensive annual actuarial review. (2) A non-GAAP measure. See pages 30 and 32 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 4Q22 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 4Q22 SIGNIFICANT ITEMS
30 (dollars in millions) * Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transactions, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes (“net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals. A reconciliation of net operating income to net income applicable to common stock is provided in the above table. QUARTERLY EARNINGS 2Q23 3Q23 4Q23 1Q24 2Q24 Insurance product margin Annuity 57.1$ 57.0$ 63.6$ 52.0$ 76.1$ Health 108.2 123.2 146.4 123.0 135.9 Life 57.9 59.8 64.6 54.6 63.1 Total insurance product margin 223.2 240.0 274.6 229.6 275.1 Allocated expenses (149.5) (153.2) (138.8) (161.6) (154.6) Income from insurance products 73.7 86.8 135.8 68.0 120.5 Fee income 0.6 (2.9) 17.8 11.3 0.8 Investment income not allocated to product lines 28.0 38.4 38.3 12.3 44.8 Expenses not allocated to product lines (21.1) 7.5 (19.8) (16.8) (17.5) Operating earnings before taxes 81.2 129.8 172.1 74.8 148.6 Income tax expense on operating income (18.9) (28.5) (38.2) (17.3) (34.0) Net operating income* 62.3 101.3 133.9 57.5 114.6 Net realized investment gains (losses) from sales, impairments and change in allowance for credit losses (31.3) (20.1) 1.4 (4.6) (21.9) Net change in market value of investments recognized in earnings (4.0) (9.2) 8.8 12.4 4.7 Changes in fair value of embedded derivative liabilities and market risk benefits 50.4 109.4 (124.6) 64.0 16.8 Fair value changes related to agent deferred compensation plan - 6.8 (10.3) - 3.5 Other (0.2) (1.1) (1.3) (0.4) (1.1) Non-operating income (loss) before taxes 14.9 85.8 (126.0) 71.4 2.0 Income tax (expense) benefit on non-operating income (loss) (3.5) (19.8) 28.4 (16.6) (0.3) Net non-operating income (loss) 11.4 66.0 (97.6) 54.8 1.7 Net income 73.7$ 167.3$ 36.3$ 112.3$ 116.3$
31 The following provides additional information regarding certain non-GAAP measures used in this presentation. A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. While management believes these measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered as substitutes for the most directly comparable GAAP measures. Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the “Investors – SEC Filings” section of CNO’s website, www.CNOinc.com. Operating earnings measures Management believes that an analysis of net income applicable to common stock before net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net change in market value of investments recognized in earnings, changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, fair value changes related to the agent deferred compensation plan, loss on extinguishment of debt, changes in the valuation allowance for deferred tax assets and other tax items and other non-operating items consisting primarily of earnings attributable to variable interest entities (“net operating income,” a non- GAAP financial measure) is important to evaluate the financial performance of the Company and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the Company’s underlying fundamentals. INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES
32 A reconciliation of net income applicable to common stock to net operating income (and related per-share amounts) is as follows: (dollars in millions, except per-share amounts) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 2Q23 3Q23 4Q23 1Q24 2Q24 Net income applicable to common stock 73.7$ 167.3$ 36.3$ 112.3$ 116.3$ Non-operating items: Net realized investment (gains) losses from sales and impairments 31.3 20.1 (1.4) 4.6 21.9 Net change in market value of investments recognized in earnings 4.0 9.2 (8.8) (12.4) (4.7) Changes in fair value of embedded derivative liabilities and market risk benefits (50.4) (109.4) 124.6 (64.0) (16.8) Fair value changes related to the agent deferred compensation plan - (6.8) 10.3 - (3.5) Other 0.2 1.1 1.3 0.4 1.1 Non-operating (income) loss before taxes (14.9) (85.8) 126.0 (71.4) (2.0) Income tax expense (benefit) on non-operating income 3.5 19.8 (28.4) 16.6 0.3 Net non-operating (income) loss (11.4) (66.0) 97.6 (54.8) (1.7) Net operating income (a non-GAAP financial measure) 62.3$ 101.3$ 133.9$ 57.5$ 114.6$ Per diluted share: Net income 0.64$ 1.46$ 0.32$ 1.01$ 1.06$ Net realized investment (gains) losses from sales and impairments (net of taxes) 0.21 0.14 (0.01) 0.03 0.15 Net change in market value of investments recognized in earnings (net of taxes) 0.02 0.06 (0.06) (0.08) (0.03) Changes in fair value of embedded derivative liabilities and market risk benefits (net of taxes) (0.33) (0.74) 0.85 (0.44) (0.12) Fair value changes related to the agent deferred compensation plan (net of taxes) - (0.05) 0.07 - (0.02) Other - 0.01 0.01 - 0.01 Net operating income (a non-GAAP financial measure) 0.54$ 0.88$ 1.18$ 0.52$ 1.05$
33 A reconciliation of operating income and shares used to calculate basic and diluted operating earnings per share is as follows: (dollars in millions, except per-share amounts, and shares in thousands) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 2Q23 3Q23 4Q23 1Q24 2Q24 Operating income 62.3$ 101.3$ 133.9$ 57.5$ 114.6$ Weighted average shares outstanding for basic earnings per share 114,273 112,689 111,590 108,964 107,731 Effect of dilutive securities on weighted average shares: Employee benefit plans 1,377 1,773 2,067 1,881 1,527 Weighted average shares outstanding for diluted earnings per share 115,650 114,462 113,657 110,845 109,258 Net operating income per diluted share 0.54$ 0.88$ 1.18$ 0.52$ 1.05$
34 Book value per diluted share Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised, restricted stock and performance units were vested, and convertible securities were converted. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments. A reconciliation from book value per share to book value per diluted share, excluding accumulated other comprehensive income (loss) is as follows: (dollars in millions, except share and per-share amounts) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 2Q23 3Q23 4Q23 1Q24 2Q24 Total shareholders' equity 1,995.8$ 1,890.1$ 2,215.6$ 2,367.7$ 2,428.9$ Shares outstanding for the period 113,673,882 112,163,169 109,357,540 108,568,594 106,513,566 Book value per share 17.56$ 16.85$ 20.26$ 21.81$ 22.80$ Total shareholders' equity 1,995.8$ 1,890.1$ 2,215.6$ 2,367.7$ 2,428.9$ Accumulated other comprehensive loss (1,733.5) (1,956.7) (1,576.8) (1,480.3) (1,464.3) Adjusted shareholders' equity excluding AOCI 3,729.3$ 3,846.8$ 3,792.4$ 3,848.0$ 3,893.2$ Shares outstanding for the period 113,673,882 112,163,169 109,357,540 108,568,594 106,513,566 Dilutive common stock equivalents related to: Stock options, restricted stock and performance units 1,629,412 1,811,501 2,392,716 1,467,901 1,626,443 Diluted shares outstanding 115,303,294 113,974,670 111,750,256 110,036,495 108,140,009 Book value per diluted share (a non-GAAP measure) 32.34$ 33.75$ 33.94$ 34.97$ 36.00$
35 Operating return measures Management believes that an analysis of net income applicable to common stock before net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net change in market value of investments recognized in earnings, changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, fair value changes related to the agent deferred compensation plan, changes in the valuation allowance for deferred tax assets and other tax items, loss on extinguishment of debt and other non-operating items consisting primarily of earnings attributable to variable interest entities (“net operating income,” a non-GAAP financial measure) is important to evaluate the financial performance of the Company and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the Company’s underlying fundamentals. Management also believes that an operating return, excluding significant items, is important as the impact of these items enhances the understanding of our operating results. This non-GAAP financial measure also differs from return on equity because accumulated other comprehensive income (loss) has been excluded from the value of equity used to determine this ratio. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. In addition, our equity includes the value of significant net operating loss carryforwards (included in income tax assets). In accordance with GAAP, these assets are not discounted, and accordingly will not provide a return to shareholders (until after it is realized as a reduction to taxes that would otherwise be paid). Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns and the comparability of these measures from period-to-period. Operating return measures are used in measuring the performance of our business units and are used as a basis for incentive compensation. INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES
36 The calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant item, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non- GAAP financial measure); and (iii) return on equity are as follows: (dollars in millions) (Continued on next page) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 2Q23 3Q23 4Q23 1Q24 2Q24 Operating income 281.7$ 305.1$ 356.1$ 355.0$ 407.3$ Operating income, excluding significant items 281.2$ 287.7$ 312.8$ 311.7$ 364.0$ Net income 286.8$ 278.2$ 276.5$ 389.6$ 432.2$ Average common equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,519.3$ 3,582.8$ 3,631.5$ 3,650.0$ 3,648.4$ Average common shareholders' equity 1,931.5$ 1,918.3$ 1,977.5$ 2,075.3$ 2,171.4$ Operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 8.0% 8.5% 9.8% 9.7% 11.2% Operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 8.0% 8.0% 8.6% 8.5% 10.0% Return on equity 14.8% 14.5% 14.0% 18.8% 19.9% Twelve Months Ended
37 The following summarizes: (i) operating earnings; (ii) significant items; (iii) operating earnings, excluding significant items; and (iv) net income (loss): (dollars in millions) (a) The significant items have been discussed in either the current or prior press releases. (Continued on next page) Net operating income Significant items (a) Net operating income, excluding significant items Net operating income, excluding significant items - trailing four quarters Net income (loss) Net income - trailing four quarters 3Q22 77.9$ -$ 77.9$ 260.1$ 175.9$ 592.6$ 4Q22 82.9 (0.5) 82.4 342.5 38.0 630.6 1Q23 58.6 - 58.6 336.6 (0.8) 446.4 2Q23 62.3 - 62.3 281.2 73.7 286.8 3Q23 101.3 (16.9) 84.4 287.7 167.3 278.2 4Q23 133.9 (26.4) 107.5 312.8 36.3 276.5 1Q24 57.5 - 57.5 311.7 112.3 389.6 2Q24 114.6 - 114.6 364.0 116.3 432.2 INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES
38 The calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant item, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non- GAAP financial measure); and (iii) return on equity are as follows: (dollars in millions) (Continued on next page) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 2Q23 3Q23 4Q23 1Q24 2Q24 Pre-tax operating earnings (a non-GAAP financial measure) 365.6$ 394.4$ 459.5$ 457.9$ 525.3$ Income tax expense (83.9) (89.3) (103.4) (102.9) (118.0) Operating return 281.7 305.1 356.1 355.0 407.3 Non-operating items: Net realized investment losses from sales and impairments (71.9) (91.3) (62.7) (54.6) (45.2) Net change in market value of investments recognized in earnings (31.9) (24.1) (6.3) 8.0 16.7 Changes in fair value of embedded derivative liabilities and market risk benefits 99.5 78.3 (29.9) 99.2 65.6 Fair value changes and amendment related to the agent deferred compensation plan 12.2 7.0 (3.5) (3.5) - Other (2.0) (5.1) (0.3) (3.0) (3.9) Non-operating income (loss) before taxes 5.9 (35.2) (102.7) 46.1 33.2 Income tax (expense) benefit on non-operating income (loss) (0.8) 8.3 23.1 (11.5) (8.3) Net non-operating income (loss) 5.1 (26.9) (79.6) 34.6 24.9 Net income 286.8$ 278.2$ 276.5$ 389.6$ 432.2$ Twelve Months Ended
39 A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows: (dollars in millions) 1Q22 2Q22 3Q22 4Q22 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,141.7$ 3,329.0$ 3,510.3$ 3,557.1$ Net operating loss carryforwards 238.2 214.7 190.9 169.0 Accumulated other comprehensive loss (561.5) (1,415.8) (1,837.8) (1,957.3) Common shareholders' equity 2,818.4$ 2,127.9$ 1,863.4$ 1,768.8$ 1Q23 2Q23 3Q23 4Q23 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,543.8$ 3,603.0$ 3,744.2$ 3,712.8$ Net operating loss carryforwards 152.4 126.3 102.6 79.6 Accumulated other comprehensive loss (1,664.4) (1,733.5) (1,956.7) (1,576.8) Common shareholders' equity 2,031.8$ 1,995.8$ 1,890.1$ 2,215.6$ 1Q24 2Q24 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,536.8$ 3,596.7$ Net operating loss carryforwards 311.2 296.5 Accumulated other comprehensive loss (1,480.3) (1,464.3) Common shareholders' equity 2,367.7$ 2,428.9$ INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES
40 A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows: (dollars in millions) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 2Q23 3Q23 4Q23 1Q24 2Q24 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,519.3$ 3,582.8$ 3,631.5$ 3,650.0$ 3,648.4$ Net operating loss carryforwards 170.7 148.6 126.4 135.1 176.2 Accumulated other comprehensive loss (1,758.5) (1,813.1) (1,780.4) (1,709.8) (1,653.2) Common shareholders' equity 1,931.5$ 1,918.3$ 1,977.5$ 2,075.3$ 2,171.4$ Trailing Four Quarter Average
41 Debt to capital ratio, excluding accumulated other comprehensive income (loss) The debt to capital ratio, excluding accumulated other comprehensive income (loss), differs from the debt to capital ratio because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. A reconciliation of these ratios is as follows: (dollars in millions) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 2022 2023 1Q24 2Q24 Corporate notes payable 1,138.8$ 1,140.5$ 1,141.0$ 1,832.3$ Total shareholders' equity 1,768.8 2,215.6 2,367.7 2,428.9 Total capital 2,907.6$ 3,356.1$ 3,508.7$ 4,261.2$ Corporate debt to capital 39.2% 34.0% 32.5% 43.0% Corporate notes payable 1,138.8$ 1,140.5$ 1,141.0$ 1,832.3$ Total shareholders' equity 1,768.8 2,215.6 2,367.7 2,428.9 Less accumulated other comprehensive (income) loss 1,957.3 1,576.8 1,480.3 1,464.3 Total capital 4,864.9$ 4,932.9$ 4,989.0$ 5,725.5$ Debt to total capital ratio, excluding AOCI (a non-GAAP financial measure) 23.4% 23.1% 22.9% 32.0% Corporate notes payable 1,832.3$ Assumed repayment of 2025 notes, net of unamortized debt issuance costs (499.0) Adjusted corporate notes payable 1,333.3$ Total shareholders' equity 2,428.9$ Less accumulated other comprehensive loss 1,464.3 Loss on assumed extinguishment of debt (0.8) Adjusted shareholders' equity 3,892.4$ Adjusted total capital 5,225.7$ Debt to total capital ratio, excluding AOCI, as adjusted for the assumed repayment of the 2025 Notes (a non-GAAP financial measure) 25.5%
v3.24.2
Cover Page
|
Jul. 29, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Document Period End Date |
Jul. 29, 2024
|
Entity Registrant Name |
CNO Financial Group, Inc.
|
Entity Incorporation, State or Country Code |
DE
|
Entity File Number |
001-31792
|
Entity Tax Identification Number |
75-3108137
|
Entity Address, Address Line One |
11299 Illinois Street
|
Entity Address, City or Town |
Carmel
|
Entity Address, State or Province |
IN
|
Entity Address, Postal Zip Code |
46032
|
City Area Code |
317
|
Local Phone Number |
817-6100
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Entity Central Index Key |
0001224608
|
Amendment Flag |
false
|
Common Stock, par value $0.01 per share |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common Stock, par value $0.01 per share
|
Trading Symbol |
CNO
|
Security Exchange Name |
NYSE
|
5.125% Subordinated Debentures due 2060 |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
5.125% Subordinated Debentures due 2060
|
Trading Symbol |
CNOpA
|
Security Exchange Name |
NYSE
|
Rights To Purchase Series F Junior Participating Preferred Stock |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Rights to purchase Series F Junior Participating Preferred Stock
|
No Trading Symbol Flag |
true
|
Security Exchange Name |
NYSE
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a security having no trading symbol.
+ References
+ Details
Name: |
dei_NoTradingSymbolFlag |
Namespace Prefix: |
dei_ |
Data Type: |
dei:trueItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=cno_A5125SubordinatedDebenturesDue2060Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=cno_RightsToPurchaseSeriesFJuniorParticipatingPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Grafico Azioni CNO Financial (NYSE:CNO)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni CNO Financial (NYSE:CNO)
Storico
Da Dic 2023 a Dic 2024